

# Current concepts in the management of Helicobacter pylori 2000 Consensus Report

Alimentary Pharmacology and Therapeutics

16, 167-180

DOI: [10.1046/j.1365-2036.2002.01169.x](https://doi.org/10.1046/j.1365-2036.2002.01169.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Alternative and rescue treatment regimens for <i>Helicobacter pylori</i> eradication. Expert Opinion on Pharmacotherapy, 2002, 3, 1301-1311.	0.9	32
2	Emergence of Tetracycline Resistance in <i>Helicobacter pylori</i> : Multiple Mutational Changes in 16S Ribosomal DNA and Other Genetic Loci. Antimicrobial Agents and Chemotherapy, 2002, 46, 3940-3946.	1.4	80
3	Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for <i>Helicobacter pylori</i> infection. American Journal of Gastroenterology, 2002, 97, 857-860.	0.2	73
4	Dyspepsia: management guidelines for the millennium. Gut, 2002, 50, iv72-iv78.	6.1	39
5	Recent developments in gastroenterology. BMJ: British Medical Journal, 2002, 325, 1399-1402.	2.4	15
6	Evaluation of the Benefits and Risks of Low-Dose Aspirin in the Secondary Prevention of Cardiovascular and Cerebrovascular Events. Archives of Internal Medicine, 2002, 162, 2197.	4.3	225
7	Causes of failure of eradication of <i>Helicobacter pylori</i> . BMJ: British Medical Journal, 2002, 325, 3-4.	2.4	35
8	The Effect of <i>Helicobacter pylori</i> Retreatment With Ranitidine Bismuth Citrate, Clarithromycin, and Metronidazole Depends on the First-Line Therapy. Journal of Clinical Gastroenterology, 2002, 35, 379-382.	1.1	7
9	Levofloxacin based regimens for the eradication of <i>Helicobacter pylori</i> . European Journal of Gastroenterology and Hepatology, 2002, 14, 1309-1312.	0.8	62
10	Dyspepsia: gaps between primary and secondary care. Digestive and Liver Disease, 2002, 34, 243-245.	0.4	2
11	The place of probiotics in human intestinal infections. International Journal of Antimicrobial Agents, 2002, 20, 313-319.	1.1	87
12	Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration. Journal of Antimicrobial Chemotherapy, 2002, 50, 699-706.	1.3	25
13	Comparison of Three Triple Regimens with Omeprazole or Ranitidine Bismuth Citrate for <i>Helicobacter pylori</i> Eradication. Scandinavian Journal of Gastroenterology, 2002, 37, 1374-1379.	0.6	23
14	Peptic-ulcer disease. Lancet, The, 2002, 360, 933-941.	6.3	199
16	Azithromycin in a triple therapy for <i>H.pylori</i> eradication in active duodenal ulcer. World Journal of Gastroenterology, 2002, 8, 879.	1.4	19
17	Uses of Stable Isotopes in the Assessment of Nutrient Status and Metabolism. Food and Nutrition Bulletin, 2002, 23, 17-20.	0.5	7
18	Gastric urease and peptic ulcer disease in Ireland in the 1940s – The Fitzgerald connection. Irish Journal of Medical Science, 2002, 171, 231-234.	0.8	0
19	Rescue therapy for <i>Helicobacter pylori</i> . Current Treatment Options in Gastroenterology, 2002, 5, 133-138.	0.3	20

#	ARTICLE	IF	CITATIONS
20	Helicobacter pylori-associated diseases. Current Gastroenterology Reports, 2002, 4, 448-454.	1.1	57
21	Treatment and management of Helicobacter pylori infection. Current Gastroenterology Reports, 2002, 4, 471-477.	1.1	5
22	Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies. Alimentary Pharmacology and Therapeutics, 2002, 16, 569-575.	1.9	51
23	Impact of Helicobacter pylori eradication on heartburn in patients with gastric or duodenal ulcer disease - results from a randomized trial programme. Alimentary Pharmacology and Therapeutics, 2002, 16, 1431-1442.	1.9	69
24	Pathogenesis of sporadic and familial gastric cancer - implications for clinical management and cancer prevention. Alimentary Pharmacology and Therapeutics, 2002, 16, 1059-1066.	1.9	39
25	Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection. Alimentary Pharmacology and Therapeutics, 2002, 16, 1457-1460.	1.9	26
26	Appropriateness of urea breath test: a prospective observational study based on Maastricht 2000 guidelines. Alimentary Pharmacology and Therapeutics, 2002, 16, 1443-1447.	1.9	12
27	Stool antigen assay (HpSA) is less reliable than urea breath test for post-treatment diagnosis of Helicobacter pylori infection. Alimentary Pharmacology and Therapeutics, 2002, 16, 1733-1738.	1.9	32
28	Fluorescence in situ hybridization vs. epsilometer test for detection of clarithromycin-susceptible and clarithromycin-resistant Helicobacter pylori strains in gastric biopsies from children. Alimentary Pharmacology and Therapeutics, 2002, 16, 2073-2079.	1.9	38
29	One-week ranitidine bismuth citrate, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese. Alimentary Pharmacology and Therapeutics, 2002, 16, 2067-2072.	1.9	12
30	Diagnosis of Helicobacter pylori infection. Alimentary Pharmacology and Therapeutics, 2002, 16, 16-23.	1.9	65
31	Treatment of Helicobacter pylori infection and factors influencing eradication. Alimentary Pharmacology and Therapeutics, 2002, 16, 24-30.	1.9	78
32	Helicobacter pylori infection in peptic ulcer haemorrhage. Alimentary Pharmacology and Therapeutics, 2002, 16, 66-78.	1.9	36
33	Impact of Furazolidone-Based Quadruple Therapy for Eradication of Helicobacter pylori after Previous Treatment Failures. Helicobacter, 2002, 7, 225-231.	1.6	62
34	Epidemiology and diagnosis of Helicobacter pylori infection. Helicobacter, 2002, 7, 8-16.	1.6	70
35	Helicobacter pylori and nonmalignant disease. Helicobacter, 2002, 7, 30-36.	1.6	13
36	Helicobacter pylori: the challenge in therapy. Helicobacter, 2002, 7, 43-49.	1.6	41
37	Helicobacter pylori infection in geriatrics. Helicobacter, 2002, 7, 56-62.	1.6	59

#	ARTICLE	IF	CITATIONS
38	Oesophageal disorders: future developments. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2002, 16, 811-833.	1.0	3
39	Effect of different probiotic preparations on anti- <i>Helicobacter pylori</i> therapy-related side effects: a parallel group, triple blind, placebo-controlled study. <i>American Journal of Gastroenterology</i> , 2002, 97, 2744-2749.	0.2	299
40	Recent Use of Proton Pump Inhibitor-Based Triple Therapies for the Eradication of <i>H. pylori</i> : A Broad Data Review. <i>Helicobacter</i> , 2003, 8, 95-104.	1.6	50
41	Lafutidine, a Novel Histamine H2-Receptor Antagonist, vs. Lansoprazole in Combination with Amoxicillin and Clarithromycin for Eradication of <i>Helicobacter pylori</i> . <i>Helicobacter</i> , 2003, 8, 111-119.	1.6	33
42	Salvage Therapy after Two or More Prior <i>Helicobacter pylori</i> Treatment Failures: the Super Salvage Regimen. <i>Helicobacter</i> , 2003, 8, 307-309.	1.6	39
43	Treatment of <i>Helicobacter Pylori</i> Infection Using a Novel Antiadhesion Compound (3'-sialyllactose) Tj ETQq1 1 0.784314 rgBT /Overload	1.6	49
44	Active and Inactive Gastroesophageal Reflux Diseases Related to <i>Helicobacter pylori</i> Therapy. <i>Helicobacter</i> , 2003, 8, 279-293.	1.6	16
45	Gastric Juice, Gastric Tissue and Blood Antibiotic Concentrations Following Omeprazole, Amoxicillin and Clarithromycin Triple Therapy. <i>Helicobacter</i> , 2003, 8, 294-299.	1.6	27
46	Treatment of <i>Helicobacter pylori</i> infection. <i>Helicobacter</i> , 2003, 8, 53-60.	1.6	38
47	Diagnosis of <i>Helicobacter pylori</i> infection. <i>Helicobacter</i> , 2003, 8, 13-20.	1.6	34
48	<i>Helicobacter pylori</i> and nonmalignant diseases. <i>Helicobacter</i> , 2003, 8, 36-43.	1.6	22
49	Eradication of <i>Helicobacter pylori</i> by 7-Day Triple-Therapy Regimens Combining Pantoprazole with Clarithromycin, Metronidazole, or Amoxicillin in Patients with Peptic Ulcer Disease: Results of Two Double-Blind, Randomized Studies. <i>Helicobacter</i> , 2003, 8, 626-642.	1.6	43
50	Conduite Ã tenir en cas dâ€™infection ÃH. pylori et de reflux gastro-Ã“sophagien. <i>Acta Endoscopica</i> , 2003, 33, 697-706.	0.0	0
51	Are dyspeptic symptoms linked to <i>Helicobacter pylori</i> ? A prospective cohort study among medical students. <i>Wiener Klinische Wochenschrift</i> , 2003, 115, 175-178.	1.0	12
52	Treatment of functional dyspepsia. <i>Current Treatment Options in Gastroenterology</i> , 2003, 6, 289-297.	0.3	9
53	Gastrointestinal lymphoma. <i>Current Treatment Options in Oncology</i> , 2003, 4, 421-430.	1.3	5
54	Noninvasive tests to diagnose <i>Helicobacter pylori</i> infection. <i>Current Gastroenterology Reports</i> , 2003, 5, 351-352.	1.1	4
55	Leydig cell death in rats exposed to bismuth subnitrate. <i>Journal of Applied Toxicology</i> , 2003, 23, 235-238.	1.4	16

#	ARTICLE	IF	CITATIONS
56	A specific anti- <i>Helicobacter pylori</i> agent NE2001: synthesis and its effect on the growth of <i>H. pylori</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 2703-2707.	1.0	9
57	Gastrointestinal and Systemic Uptake of Bismuth in Mice after Oral Exposure. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2003, 93, 82-90.	0.0	15
58	The burden of <i>Helicobacter pylori</i> infection in Europe. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 38-44.	1.9	16
59	Probiotics and <i>Helicobacter pylori</i> . <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2003, 17, 785-791.	1.0	50
60	<i>Lactobacillus gasseri</i> OLL2716 as a probiotic in clarithromycin-resistant <i>Helicobacter pylori</i> infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003, 18, 986-991.	1.4	66
62	Efficacy of quadruple therapy for <i>Helicobacter pylori</i> eradication after failure of proton pump inhibitor-based triple therapy in Singapore. <i>Chinese Journal of Digestive Diseases</i> , 2003, 4, 35-39.	1.1	2
63	<i>Helicobacter pylori</i> hiccup. <i>Internal Medicine Journal</i> , 2003, 33, 398-398.	0.5	2
64	Non-invasive techniques for the diagnosis of <i>Helicobacter pylori</i> infection. <i>Clinical Microbiology and Infection</i> , 2003, 9, 489-496.	2.8	40
65	Overview: initial and long-term management of gastro-oesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 53-57.	1.9	21
66	Test and treat or test and scope for <i>Helicobacter pylori</i> infection. Any change in gastric cancer prevention?. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 82-88.	1.9	6
67	Diagnosis and treatment of <i>Helicobacter</i> : a 2002 updated review. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 89-97.	1.9	27
68	Once-daily, low-cost, highly effective <i>Helicobacter pylori</i> treatment to family members of gastric cancer patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 131-136.	1.9	18
69	Early events in proton pump inhibitor-associated exacerbation of corpus gastritis. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 193-200.	1.9	48
70	Efficacy and safety of single-triple capsules of bismuth biscaltrate, metronidazole and tetracycline, given with omeprazole, for the eradication of <i>Helicobacter pylori</i> : an international multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 415-420.	1.9	91
71	<i>Helicobacter pylori</i> strains and histologically-related lesions affect the outcome of triple eradication therapy: a study from southern Italy. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 421-428.	1.9	22
72	Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 553-560.	1.9	113
73	High eradication rates of <i>Helicobacter pylori</i> with a new sequential treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 719-726.	1.9	199
74	Stool antigen for the diagnosis of <i>Helicobacter pylori</i> infection in cirrhosis: comparative usefulness of three different methods. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 727-731.	1.9	16

#	ARTICLE	IF	CITATIONS
75	A rapid, low-dose, 13 C-urea tablet for the detection of <i>Helicobacter pylori</i> infection before and after treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 793-798.	1.9	42
76	Antigen stool test for assessment of <i>Helicobacter pylori</i> infection in patients with upper gastrointestinal bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 1075-1084.	1.9	29
77	One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 1381-1387.	1.9	30
78	Triple vs. quadruple therapy for treating <i>Helicobacter pylori</i> infection: a meta-analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 1137-1143.	1.9	109
79	Review article: clinic-based testing for <i>Helicobacter pylori</i> infection by enzyme immunoassay of faeces, urine and saliva. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 1345-1354.	1.9	41
80	Review article: the treatment of refractory <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 1333-1343.	1.9	176
81	Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of <i>Helicobacter pylori</i> . <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 347-353.	1.9	54
82	High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 101-107.	1.9	60
83	Meta-analysis: the relationship between <i>Helicobacter pylori</i> infection and gastro-oesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 279-289.	1.9	78
84	Levofloxacin-based triple therapy vs. quadruple therapy in second-line <i>Helicobacter pylori</i> treatment: a randomized trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 627-633.	1.9	95
85	Sequential treatment for <i>Helicobacter pylori</i> eradication in duodenal ulcer patients: improving the cost of pharmacotherapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 641-646.	1.9	40
86	<i>Helicobacter pylori</i> eradication is beneficial in the treatment of functional dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 615-625.	1.9	71
87	Low and high doses of rabeprazole vs. omeprazole for cure of <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 1017-1021.	1.9	16
88	Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for <i>Helicobacter pylori</i> eradication. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 647-654.	1.9	84
89	Randomized study of different "second-line" therapies for <i>Helicobacter pylori</i> infection after failure of the standard "Maastricht triple therapy". <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 815-820.	1.9	56
90	Role of antibiotic sensitivity testing before first-line <i>Helicobacter pylori</i> eradication treatments. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 821-827.	1.9	39
91	Second-line treatment for failure to eradicate <i>Helicobacter pylori</i> : a randomized trial comparing four treatment strategies. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 791-797.	1.9	87
92	Esomeprazole-based one-week triple therapy with clarithromycin and metronidazole is effective in eradicating <i>Helicobacter pylori</i> in the absence of antimicrobial resistance. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 799-804.	1.9	24

#	ARTICLE	IF	CITATIONS
93	Diagnostic methods for <i>Helicobacter pylori</i> detection and eradication. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 273-283.	1.1	18
97	Functional dyspepsia: evaluation and treatment. <i>Gastroenterology Clinics of North America</i> , 2003, 32, 577-599.	1.0	17
98	Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of <i>Helicobacter pylori</i> . <i>Clinical Gastroenterology and Hepatology</i> , 2003, 1, 273-278.	2.4	73
100	Dyspepsia1 Loren Laine, M.D.Clinical Management EditorUniversity of Southern CaliforniaLos Angeles, California. <i>Gastroenterology</i> , 2003, 125, 1219-1226.	0.6	19
101	Goals of Therapy and Guidelines for Treatment Success in Symptomatic Gastroesophageal Reflux Disease Patients. <i>American Journal of Gastroenterology</i> , 2003, 98, S31-S39.	0.2	69
102	Pantoprazole. <i>Drugs</i> , 2003, 63, 101-133.	4.9	135
103	Evaluation of dyspeptic symptoms in patients with and without <i>Helicobacter pylori</i> infection and normal upper gastrointestinal endoscopy. <i>Digestive and Liver Disease</i> , 2003, 35, 138-142.	0.4	9
104	<i>Helicobacter pylori</i> testing in patients with peptic ulcer bleeding. <i>Digestive and Liver Disease</i> , 2003, 35, 215-216.	0.4	6
105	A third-line levofloxacin-based rescue therapy for <i>Helicobacter pylori</i> eradication. <i>Digestive and Liver Disease</i> , 2003, 35, 232-236.	0.4	92
106	The stomach and iron deficiency anaemia: a forgotten link. <i>Digestive and Liver Disease</i> , 2003, 35, 288-295.	0.4	80
107	A clinical practice viewpoint: to culture or not to culture <i>Helicobacter pylori</i> ?. <i>Digestive and Liver Disease</i> , 2003, 35, 357-361.	0.4	74
108	Treatment options for patients with <i>Helicobacter pylori</i> infection resistant to one or more eradication attempts. <i>Digestive and Liver Disease</i> , 2003, 35, 523-528.	0.4	36
109	Breath test is very reliable for diagnosis of <i>Helicobacter pylori</i> infection in real clinical practice. <i>Digestive and Liver Disease</i> , 2003, 35, 612-618.	0.4	25
110	Use of bovine lactoferrin for <i>Helicobacter pylori</i> eradication. <i>Digestive and Liver Disease</i> , 2003, 35, 706-710.	0.4	72
111	Comparable <i>Helicobacter pylori</i> eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study. <i>Digestive and Liver Disease</i> , 2003, 35, 763-767.	0.4	16
112	Cost-effectiveness of routine endoscopic biopsies for <i>Helicobacter pylori</i> detection in patients with non-ulcer dyspepsia. <i>Gastrointestinal Endoscopy</i> , 2003, 58, 14-22.	0.5	7
113	Yield of endoscopy in dyspepsia and concurrent treatment with proton pump inhibitors: The blind leading the blind?. <i>Gastrointestinal Endoscopy</i> , 2003, 58, 89-92.	0.5	4
114	Validation of the accuracy of the <i>H. pylori</i> stool antigen test (HpSA) in the Japanese population. <i>Digestive and Liver Disease</i> , 2003, 35, 62-63.	0.4	4

#	ARTICLE	IF	CITATIONS
115	The role of probiotics in the treatment and prevention of <i>Helicobacter pylori</i> infection. <i>International Journal of Antimicrobial Agents</i> , 2003, 22, 360-366.	1.1	171
116	Prevalence of <i>Helicobacter pylori</i> in patients with gastro-oesophageal reflux disease: systematic review. <i>BMJ: British Medical Journal</i> , 2003, 326, 737-737.	2.4	274
117	Gastritis and Peptic Ulcer. <i>Medicine</i> , 2003, 31, 15-18.	0.2	3
118	Is there a link between environmental factors and a genetic predisposition to cancer? A lesson from a familial cluster of gastric cancers. <i>European Journal of Cancer</i> , 2003, 39, 1619-1624.	1.3	16
119	Good bugs and bad bugs: indications and therapies for <i>Helicobacter pylori</i> eradication. <i>Current Opinion in Pharmacology</i> , 2003, 3, 480-485.	1.7	5
120	Comparative Classification and Grading of <i>Helicobacter pylori</i> Gastritis in Patients with Gastric Cancer and Patients with Functional Dyspepsia. <i>Scandinavian Journal of Gastroenterology</i> , 2003, 38, 707-711.	0.6	13
121	“Serological biopsy”™ in first-degree relatives of patients with gastric cancer affected by <i>Helicobacter pylori</i> infection. <i>Scandinavian Journal of Gastroenterology</i> , 2003, 38, 1223-1227.	0.6	37
122	Prevalence of low vitamin B12 and high homocysteine in serum in an elderly male population: association with atrophic gastritis and <i>Helicobacter pylori</i> infection. <i>Scandinavian Journal of Gastroenterology</i> , 2003, 38, 1209-1216.	0.6	78
123	Antimicrobial activity of esomeprazole versus omeprazole against <i>Helicobacter pylori</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 439-442.	1.3	57
124	Maintenance Treatment Is Not Necessary After <i>Helicobacter pylori</i> Eradication and Healing of Bleeding Peptic Ulcer. <i>Archives of Internal Medicine</i> , 2003, 163, 2020.	4.3	29
125	Comparison of three stool antigen tests for <i>Helicobacter pylori</i> detection. <i>Journal of Clinical Pathology</i> , 2003, 56, 769-771.	1.0	37
126	Real-Time PCR Assay for Rapid and Accurate Detection of Point Mutations Conferring Resistance to Clarithromycin in <i>Helicobacter pylori</i> . <i>Journal of Clinical Microbiology</i> , 2003, 41, 397-402.	1.8	206
127	Detection of <i>Helicobacter pylori</i> in Paraffin-Embedded and in Shock-Frozen Gastric Biopsy Samples by Fluorescent In Situ Hybridization. <i>Journal of Clinical Microbiology</i> , 2003, 41, 813-815.	1.8	29
128	Mastic gum has no effect on <i>Helicobacter pylori</i> load in vivo. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 52, 522-523.	1.3	39
129	Effect of <i>Helicobacter pylori</i> eradication on development of dyspeptic and reflux disease in healthy asymptomatic subjects. <i>Gut</i> , 2003, 52, 1543-1547.	6.1	28
130	Gastrointestinal and Systemic Uptake of Bismuth in Mice after Oral Exposure. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2003, 93, 82-90.	0.0	19
131	Current Role of <i>Helicobacter pylori</i> Stool Tests. <i>Digestion</i> , 2003, 68, 119-123.	1.2	11
132	Monotherapy with mastic does not eradicate <i>Helicobacter pylori</i> infection from mice. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 367-371.	1.3	41



#	ARTICLE	IF	CITATIONS
133	Helicobacter pylori resistance to antibiotics: prevalence, mechanism, detection. What's new? , 2003, , 363-371.		5
134	Lack of accuracy of the noninvasive Helicobacter pylori stool antigen test in patients with gastroduodenal ulcer bleeding. American Journal of Gastroenterology, 2003, 98, 798-801.	0.2	31
135	The Changing Epidemiology of Gerd: Geography and Helicobacter Pylori. American Journal of Gastroenterology, 2003, 98, 1462-1470.	0.2	69
136	Susceptibility of Helicobacter Pylori To Metronidazole. American Journal of Gastroenterology, 2003, 98, 2157-2161.	0.2	13
137	Endoscopic surveillance of premalignant gastric lesions. Gut, 2003, 52, 152-a-153.	6.1	2
138	Gastric Transitional Zones, Areas where Helicobacter Treatment Fails: Results of a Treatment Trial Using the Sydney Strain Mouse Model. Antimicrobial Agents and Chemotherapy, 2003, 47, 2249-2255.	1.4	29
139	Eradication of Helicobacter pylori and use of antisecretory drugs: population based cohort study. BMJ: British Medical Journal, 2003, 327, 603-603.	2.4	11
140	Helicobacter pylori. New England Journal of Medicine, 2003, 348, 363-365.	13.9	1
141	The Clinical Role of Cytochrome P450 Genotypes in Helicobacter Pylori Management. American Journal of Gastroenterology, 2003, 98, 1010-1015.	0.2	66
142	Helicobacter pylori. Current Opinion in Infectious Diseases, 2003, 16, 445-451.	1.3	55
143	Role of Therapy or Monitoring in Preventing Progression to Gastric Cancer. Journal of Clinical Gastroenterology, 2003, 36, S50-60S.	1.1	21
144	Detection of Helicobacter pylori in the Setting of Acute Upper Gastrointestinal Bleeding. Journal of Clinical Gastroenterology, 2003, 37, 6-8.	1.1	6
145	One-Day Quadruple Therapy Compared With 7-Day Triple Therapy for Helicobacter pylori Infection. Archives of Internal Medicine, 2003, 163, 2079.	4.3	28
146	Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I. European Journal of Gastroenterology and Hepatology, 2003, 15, 885-891.	0.8	213
147	The management of peptic ulcer disease. Current Opinion in Gastroenterology, 2003, 19, 533-539.	1.0	3
148	Helicobacter pylori in Children and Adolescents: Increase of Primary Clarithromycin Resistance, 1997-2000. Journal of Pediatric Gastroenterology and Nutrition, 2003, 36, 368-371.	0.9	50
149	13C-Urea Breath Test, Referral Patterns, and Results in Children. Journal of Clinical Gastroenterology, 2003, 37, 142-146.	1.1	25
150	Survey of the Opinions, Knowledge and Practices of Surgeons and Internists Regarding Helicobacter pylori Test-and-Treat Policy. Journal of Clinical Gastroenterology, 2003, 36, 139-143.	1.1	6

#	ARTICLE	IF	CITATIONS
151	Gastric Ulcers and GERD. <i>Clinical Nurse Specialist</i> , 2003, 17, 286-289.	0.3	32
152	Eradication therapy for peptic ulcer disease in <i>Helicobacter pylori</i> positive patients. , 2003, , CD003840.		25
153	<i>Helicobacter pylori</i> Infection in the Elderly. , 2003, 32, 128-144.		1
154	What are the Global Response Rates to <i>Helicobacter pylori</i> Eradication Therapy?. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2003, 17, 25B-29B.	1.8	13
155	How Can the Current Strategies for <i>Helicobacter pylori</i> Eradication Therapy be Improved?. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2003, 17, 36B-40B.	1.8	77
156	<i>Helicobacter pylori</i> Twenty Years on.... <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2003, 17, 7B-7B.	1.8	2
157	<i>Helicobacter pylori</i> : a clinician's view. <i>British Journal of Hospital Medicine</i> , 2003, 64, 535-538.	0.3	5
158	<i>Helicobacter pylori</i> Management: How to Improve the Therapeutic Confusion in Practice. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2003, 17, 21B-24B.	1.8	3
159	Dispepsia ed <i>Helicobacter pylori</i> . <i>Microbiologia Medica</i> , 2003, 18, .	0.3	0
160	What Constitutes Failure for <i>Helicobacter pylori</i> Eradication Therapy?. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2003, 17, 53B-57B.	1.8	13
161	Functional dyspepsia: relationship between clinical subgroups and <i>Helicobacter pylori</i> status in Western Turkey. <i>Brazilian Journal of Medical and Biological Research</i> , 2003, 36, 747-751.	0.7	6
162	Duodenal Ulcer. , 2004, , 645-652.		1
163	<i>Helicobacter pylori</i> -induced gastritis: pathophysiology, assessment and treatment. <i>Nurse Prescribing</i> , 2004, 2, 219-223.	0.1	2
164	Low eradication rate of <i>Helicobacter pylori</i> with triple 7-14 days and quadruple therapy in Turkey. <i>World Journal of Gastroenterology</i> , 2004, 10, 668.	1.4	99
165	Detection of <i>Helicobacter Pylori</i> by PCR on Gastric Biopsy Specimens Taken for CP Test: Comparison with Histopathological Analysis. <i>International Journal of Immunopathology and Pharmacology</i> , 2004, 17, 77-82.	1.0	7
166	<i>Helicobacter pylori</i> antibiotic resistance patterns and genotypes in adult dyspeptic patients from a regional population in North Wales. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 54, 435-440.	1.3	45
167	Age-Dependent Accuracy of <i>Helicobacter pylori</i> Antibody Assays for Adults, with Special Emphasis on Atrophic Gastritis. <i>Vaccine Journal</i> , 2004, 11, 1185-1188.	2.6	16
168	Evaluation of Commercial Immunoassays for Detection of Antibody against <i>Helicobacter pylori</i> in Thai Dyspeptic Patients. <i>Vaccine Journal</i> , 2004, 11, 618-620.	2.6	8

#	ARTICLE	IF	CITATIONS
169	Antimicrobial Susceptibility of <i>Helicobacter pylori</i> Strains Isolated in Bangladesh. <i>Journal of Clinical Microbiology</i> , 2004, 42, 4856-4858.	1.8	68
170	<i>Helicobacter pylori</i> test and eradicate versus prompt endoscopy for management of dyspeptic patients: 6.7 year follow up of a randomised trial. <i>Gut</i> , 2004, 53, 1758-1763.	6.1	46
171	<EMPH TYPE="ITAL"> <i>Helicobacter pylori</i> </EMPH> Infection and Gastric Cancerâ€™ For Want of More Outcomes. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 244.	3.8	34
172	Managing Gastro-Oesophageal Reflux Disease in the Older Patient. <i>Digestion</i> , 2004, 69, 17-24.	1.2	10
173	Clinical Usefulness of Serum Pepsinogen II in the Management of <i> <i>Helicobacter pylori</i> </i> Infection. <i>Digestion</i> , 2004, 70, 167-172.	1.2	21
174	Effect of <i>Helicobacter pylori</i> eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, randomised trial. <i>Gut</i> , 2004, 53, 174-179.	6.1	61
175	Role of the <i>rdxA</i> and <i>frxA</i> genes in oxygen-dependent metronidazole resistance of <i>Helicobacter pylori</i> . <i>Journal of Medical Microbiology</i> , 2004, 53, 1123-1128.	0.7	43
176	Bacteriostatic and Bactericidal Activity of Rabeprazole Against<i> <i>Helicobacter pylori</i> </i>. <i>Journal of Chemotherapy</i> , 2004, 16, 612-613.	0.7	1
177	Sensitivity of a Novel Stool Antigen Test for Detection of <i>Helicobacter pylori</i> in Adult Outpatients before and after Eradication Therapy. <i>Journal of Clinical Microbiology</i> , 2004, 42, 1319-1321.	1.8	25
178	Treat the Patients' Main Dyspepsia Complaint, not the ROME Criteria. <i>American Journal of Gastroenterology</i> , 2004, 99, 1059-1062.	0.2	10
179	Serological Markers for Gastric Atrophy in Asymptomatic Patients Infected with <i>Helicobacter pylori</i> . <i>American Journal of Gastroenterology</i> , 2004, 99, 1910-1915.	0.2	40
180	Effect of Proton Pump Inhibitors and Antacid Therapy on <sup>13</sup> C Urea Breath Tests and Stool Test for <i>Helicobacter Pylori</i> Infection. <i>American Journal of Gastroenterology</i> , 2004, 99, 823-829.	0.2	113
181	Functional Dyspepsia: Motor Abnormalities, Sensory Dysfunction, and Therapeutic Options. <i>American Journal of Gastroenterology</i> , 2004, 99, 739-749.	0.2	28
182	<i>Helicobacter pylori</i> eradication does not exacerbate gastro-oesophageal reflux disease. <i>Gut</i> , 2004, 53, 312-313.	6.1	21
183	Management guidelines for <i>Helicobacter pylori</i> infection: Utilization by paediatric gastroenterologists in Australasia. <i>Journal of Paediatrics and Child Health</i> , 2004, 40, 195-200.	0.4	1
184	Consensus on the management of <i>Helicobacter pylori</i> infection: Tongcheng, Anhui Province, 2003. <i>Chinese Journal of Digestive Diseases</i> , 2004, 5, 186-188.	1.1	4
185	Efficient and non-invasive method for investigating <i>Helicobacter pylori</i> in gravida with hyperemesis gravidarum: <i>Helicobacter pylori</i> stool antigen test. <i>Journal of Obstetrics and Gynaecology Research</i> , 2004, 30, 136-141.	0.6	31
186	Asia-Pacific consensus on gastroesophageal reflux disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, 353-356.	1.4	14

#	ARTICLE	IF	CITATIONS
187	Helicobacter pylori: Why are eradication results so variable?. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, 606-609.	1.4	12
188	Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of H. pylori-positive primary care patients with uninvestigated dyspepsia. Alimentary Pharmacology and Therapeutics, 2004, 19, 349-358.	1.9	39
189	Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non-ulcer dyspepsia. Alimentary Pharmacology and Therapeutics, 2004, 19, 993-998.	1.9	31
190	High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. Alimentary Pharmacology and Therapeutics, 2004, 19, 789-795.	1.9	98
191	Primary Helicobacter pylori resistance to metronidazole and clarithromycin in the Finnish population. Alimentary Pharmacology and Therapeutics, 2004, 19, 1009-1017.	1.9	30
192	The importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication. Alimentary Pharmacology and Therapeutics, 2004, 19, 1315-1321.	1.9	18
193	DNA typing for Helicobacter pylori isolates from eradication-failed patients: comparison of the isolates before and after therapy. Alimentary Pharmacology and Therapeutics, 2004, 20, 39-47.	1.9	3
194	Prevalence of symptomatic gastro-oesophageal reflux disease in Japanese patients with peptic ulcer disease after eradication of Helicobacter pylori infection. Alimentary Pharmacology and Therapeutics, 2004, 20, 107-111.	1.9	16
195	Seven-day therapy for Helicobacter pylori in the United States. Alimentary Pharmacology and Therapeutics, 2004, 20, 99-107.	1.9	146
196	Helicobacter pylori infection: anything new should we know?. Alimentary Pharmacology and Therapeutics, 2004, 20, 31-41.	1.9	19
197	What the physician needs to know for correct management of gastro-oesophageal reflux disease and dyspepsia. Alimentary Pharmacology and Therapeutics, 2004, 20, 23-30.	1.9	13
198	Helicobacter pylori eradication in children and adolescents by a once daily 6-day treatment with or without a proton pump inhibitor in a double-blind randomized trial. Alimentary Pharmacology and Therapeutics, 2004, 20, 295-302.	1.9	13
199	A rapid immunochromatographic assay for Helicobacter pylori in stool before and after treatment. Alimentary Pharmacology and Therapeutics, 2004, 20, 469-474.	1.9	27
200	Use of anti-secretory medication: a population-based cohort study. Alimentary Pharmacology and Therapeutics, 2004, 20, 577-583.	1.9	42
201	The effect of Helicobacter pylori and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis. Alimentary Pharmacology and Therapeutics, 2004, 20, 733-744.	1.9	68
202	Review article: 13 C-urea breath test in the diagnosis of Helicobacter pylori infection - a critical review. Alimentary Pharmacology and Therapeutics, 2004, 20, 1001-1017.	1.9	305
203	Review article: oesophageal complications and consequences of persistent gastro-oesophageal reflux disease. Alimentary Pharmacology and Therapeutics, 2004, 20, 47-56.	1.9	38
204	Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Alimentary Pharmacology and Therapeutics, 2004, 20, 1071-1082.	1.9	181

#	ARTICLE	IF	CITATIONS
205	Meta-analysis: the diagnostic value of alarm symptoms for upper gastrointestinal malignancy. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 1045-1052.	1.9	65
206	<i>Bacillus clausii</i> therapy to reduce side-effects of anti- <i>Helicobacter pylori</i> treatment: randomized, double-blind, placebo controlled trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 1181-1188.	1.9	156
207	Trends in peptic ulcer pharmacotherapy. <i>Fundamental and Clinical Pharmacology</i> , 2004, 18, 23-31.	1.0	27
208	CYP2C19 Polymorphism and Proton Pump Inhibitors. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2004, 95, 2-8.	1.2	138
209	Uninvestigated dyspepsia and non-ulcer dyspepsia-the use of endoscopy and the roles of <i>Helicobacter pylori</i> eradication and antisecretory therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 1-8.	1.9	30
210	Should NSAID/low-dose aspirin takers be tested routinely for <i>H. pylori</i> infection and treated if positive? Implications for primary risk of ulcer and ulcer relapse after initial healing. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 9-16.	1.9	54
211	Particularités des complications digestives hautes des anti-inflammatoires non stéroïdiens chez le sujet âgé et prévention. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2004, 71, S161-S166.	0.0	0
212	Reliable detection of macrolide-resistant <i>Helicobacter pylori</i> via fluorescence in situ hybridization in formalin-fixed tissue. <i>Modern Pathology</i> , 2004, 17, 684-689.	2.9	32
215	False Negative Urea Breath Tests with H2-Receptor Antagonists: Interactions Between <i>Helicobacter pylori</i> Density and pH. <i>Helicobacter</i> , 2004, 9, 17-27.	1.6	47
216	Serological Responses of FldA and Small-Molecular-Weight Proteins of <i>Helicobacter pylori</i> : Correlation with the Presence of the Gastric MALT Tissue. <i>Helicobacter</i> , 2004, 9, 81-86.	1.6	8
217	<i>Helicobacter pylori</i> Infection in Turkish Children: Comparison of Diagnostic Tests, Evaluation of Eradication Rate, and Changes in Symptoms after Eradication. <i>Helicobacter</i> , 2004, 9, 242-248.	1.6	50
218	Stool Antigen Test for the Diagnosis of <i>Helicobacter pylori</i> Infection: a Systematic Review. <i>Helicobacter</i> , 2004, 9, 347-368.	1.6	176
219	Dual vs. Triple Therapy for Childhood <i>Helicobacter pylori</i> Gastritis: a Double-Blind Randomized Multicentre Trial. <i>Helicobacter</i> , 2004, 9, 293-301.	1.6	33
220	<i>Helicobacter pylori</i> and Nonmalignant Diseases. <i>Helicobacter</i> , 2004, 9, 29-34.	1.6	7
221	Therapy of <i>Helicobacter pylori</i> . <i>Helicobacter</i> , 2004, 9, 42-48.	1.6	37
222	<i>Helicobacter pylori</i> Infection in Pediatrics. <i>Helicobacter</i> , 2004, 9, 49-56.	1.6	20
223	Role of Noninvasive Tests (13C-Urea Breath Test and Stool Antigen Test) as Additional Tools in Diagnosis of <i>Helicobacter Pylori</i> Infection in Patients with Atrophic Body Gastritis. <i>Helicobacter</i> , 2004, 9, 436-442.	1.6	44
224	The Interleukin-1 RN Polymorphism and <i>Helicobacter pylori</i> Infection in the Development of Duodenal Ulcer. <i>Helicobacter</i> , 2004, 9, 605-613.	1.6	20

#	ARTICLE	IF	CITATIONS
225	Multicenter Comparison of Rapid Lateral Flow Stool Antigen Immunoassay and Stool Antigen Enzyme Immunoassay for the Diagnosis of <i>Helicobacter pylori</i> Infection in Children. <i>Helicobacter</i> , 2004, 9, 669-673.	1.6	48
226	Comparison of two Different Stool Antigen Tests for the Primary Diagnosis of <i>Helicobacter pylori</i> Infection in Turkish Patients with Dyspepsia. <i>Helicobacter</i> , 2004, 9, 657-662.	1.6	25
227	Open, Randomized Multicenter Comparative Trial of Rabeprazole, Ofloxacin and Amoxicillin Therapy for <i>Helicobacter pylori</i> Eradication: 7 vs. 14-Day Treatment. <i>Helicobacter</i> , 2004, 9, 417-421.	1.6	16
228	Current approaches to prevent NSAID-induced gastropathy - COX selectivity and beyond. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 587-600.	1.1	102
229	Effect of <i>Helicobacter pylori</i> eradication in the treatment of Japanese patients with chronic idiopathic urticaria. <i>Journal of Gastroenterology</i> , 2004, 39, 827-830.	2.3	63
230	Second-line treatment for <i>Helicobacter pylori</i> infection in Japan: proton pump inhibitor-based amoxicillin and metronidazole regimen. <i>Journal of Gastroenterology</i> , 2004, 39, 1051-1055.	2.3	22
231	<sup>13</sup> C-Urea Breath Test for Diagnosis of <i>Helicobacter pylori</i> Infection in the Elderly. <i>Digestive Diseases and Sciences</i> , 2004, 49, 1840-1844.	1.1	12
233	<i>Helicobacter pylori</i> and gastroesophageal reflux disease. Current Treatment Options in <i>Gastroenterology</i> , 2004, 7, 59-70.	0.3	21
234	Beta-lactamase inhibitor enhances <i>Helicobacter pylori</i> eradication rate. <i>Journal of Internal Medicine</i> , 2004, 255, 125-129.	2.7	16
235	Expression of COX-2, mPGE-synthase1, MDR-1 (P-gp), and Bcl-xL: a molecular pathway of <i>H. pylori</i> -related gastric carcinogenesis. <i>Journal of Pathology</i> , 2004, 202, 305-312.	2.1	80
236	The diagnostic value of endoscopy and <i>Helicobacter pylori</i> tests for peptic ulcer patients in late post-treatment setting. <i>BMC Gastroenterology</i> , 2004, 4, 27.	0.8	4
237	Non-invasive diagnosis of <i>Helicobacter pylori</i> infection: simplified <sup>13</sup> C-urea breath test, stool antigen testing, or DNA PCR in human feces in a clinical laboratory setting?. <i>Clinical Biochemistry</i> , 2004, 37, 261-267.	0.8	21
238	CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 201-209.	2.3	93
239	Diagnostic approach to dyspepsia. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2004, 18, 681-693.	1.0	13
240	An evaluation of current GERD therapy. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2004, 18, 39-45.	1.0	7
241	Rapid Detection of Point Mutations in the <i>gyrA</i> Gene of <i>Helicobacter pylori</i> Conferring Resistance to Ciprofloxacin by a Fluorescence Resonance Energy Transfer-Based Real-Time PCR Approach. <i>Journal of Clinical Microbiology</i> , 2004, 42, 2241-2246.	1.8	49
242	Cure of <i>Helicobacter pylori</i> infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. <i>Gut</i> , 2004, 53, 12-20.	6.1	178
243	A 10-day levofloxacin-based therapy in patients with resistant infection: A controlled trial. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 997-1002.	2.4	80

#	ARTICLE	IF	CITATIONS
245	Polymorphism of interleukin-1? affects the eradication rates of by triple therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 22-30.	2.4	66
247	Pathophysiology and treatment of functional dyspepsia. <i>Gastroenterology</i> , 2004, 127, 1239-1255.	0.6	426
248	Empirical <i>Helicobacter pylori</i> "rescue" therapy after failure of two eradication treatments. <i>Digestive and Liver Disease</i> , 2004, 36, 7-12.	0.4	20
249	The prolongation of triple therapy for <i>Helicobacter pylori</i> does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study. <i>Digestive and Liver Disease</i> , 2004, 36, 322-326.	0.4	66
250	Towards the ideal regimen for <i>Helicobacter pylori</i> eradication: the search continues. <i>Digestive and Liver Disease</i> , 2004, 36, 243-247.	0.4	17
251	Sequential therapy; a new treatment for <i>Helicobacter pylori</i> infection. <i>Digestive and Liver Disease</i> , 2004, 36, 311-314.	0.4	17
252	Diagnosis of <i>Helicobacter pylori</i> infection in dyspeptic patients by stool antigen detection. <i>Digestive and Liver Disease</i> , 2004, 36, 450-454.	0.4	19
253	Stool test for <i>Helicobacter pylori</i> . <i>Digestive and Liver Disease</i> , 2004, 36, 446-447.	0.4	7
254	Admission rates for peptic ulcer in the Trent Region, UK, 1972"2000. <i>Digestive and Liver Disease</i> , 2004, 36, 577-588.	0.4	35
255	Measuring dyspepsia: a new severity index validated in Bologna. <i>Digestive and Liver Disease</i> , 2004, 36, 806-810.	0.4	19
256	Application of 3" mismatched reverse primer PCR compared with real-time PCR and PCR-RFLP for the rapid detection of 23S rDNA mutations associated with clarithromycin resistance in <i>Helicobacter pylori</i> . <i>International Journal of Antimicrobial Agents</i> , 2004, 23, 349-355.	1.1	19
257	High levels of dual resistance to clarithromycin and metronidazole and in vitro activity of levofloxacin against <i>Helicobacter pylori</i> isolates from patients after failure of therapy. <i>International Journal of Antimicrobial Agents</i> , 2004, 24, 433-438.	1.1	38
258	Basis for the Management of Drug-Resistant <i>Helicobacter pylori</i> Infection. <i>Drugs</i> , 2004, 64, 1893-1904.	4.9	65
259	H <i>pylori</i> antibiotic resistance: prevalence, importance, and advances in testing. <i>Gut</i> , 2004, 53, 1374-1384.	6.1	788
260	Pretreatment antimicrobial susceptibility testing is not cost saving in the standard eradication of. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 85.	2.4	10
261	Evaluation of a near-patient fecal antigen test for the assessment of <i>Helicobacter pylori</i> status. <i>Diagnostic Microbiology and Infectious Disease</i> , 2004, 48, 145-147.	0.8	12
263	Second-line and third-line trial for <i>helicobacter pylori</i> infection in patients with duodenal ulcers: A prospective, crossover, controlled study. <i>Current Therapeutic Research</i> , 2004, 65, 13-25.	0.5	4
266	Protocolo terap?utico de la ?lcera duodenal. <i>Medicine</i> , 2004, 9, 131-133.	0.0	0

#	ARTICLE	IF	CITATIONS
268	The Effect of Helicobacter pylori Eradication on Gastroesophageal Reflux Disease. Journal of Clinical Gastroenterology, 2004, 38, 750-755.	1.1	19
269	Helicobacter pylori Infection and Dyspepsia in Pregnancy. Obstetrics and Gynecology, 2004, 103, 1005.	1.2	0
271	Early Effects of Helicobacter pylori Infection in Patients Undergoing Bariatric Surgery. Archives of Surgery, 2004, 139, 1094.	2.3	56
272	Diagnostic tests for childhood Helicobacter pylori Infection: Invasive, Noninvasive or Both?. Journal of Pediatric Gastroenterology and Nutrition, 2004, 39, 482-484.	0.9	14
273	High-dose Versus Low-dose Clarithromycin in 1-week Triple Therapy, Including Rabeprazole and Levofloxacin, for Helicobacter pylori Eradication. Journal of Clinical Gastroenterology, 2004, 38, 110-114.	1.1	18
274	Ranitidine???bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment. European Journal of Gastroenterology and Hepatology, 2004, 16, 987-990.	0.8	6
275	Pantoprazole based therapies in Helicobacter pylori eradication. European Journal of Gastroenterology and Hepatology, 2004, 16, 89-99.	0.8	28
276	Cost-effectiveness and long-term impact of Helicobacter pylori ???test and treat??? service in reducing open access endoscopy referrals. European Journal of Gastroenterology and Hepatology, 2004, 16, 981-986.	0.8	10
277	Histological changes in the gastric mucosa after Helicobacter pylori eradication. European Journal of Gastroenterology and Hepatology, 2004, 16, 1183-1188.	0.8	16
278	Functional dyspepsia. Current Opinion in Gastroenterology, 2004, 20, 546-550.	1.0	12
279	Application of Maastricht 2-2000 Guidelines for the Management of Helicobacter pylori Among Specialists and Primary Care Physicians in Israel. Journal of Clinical Gastroenterology, 2004, 38, 322-325.	1.1	25
280	Genetic Screening for Familial Gastric Cancer. Hereditary Cancer in Clinical Practice, 2004, 2, 51.	0.6	34
281	Oral Toxicity of Bismuth in Rat: Single and 28â€œDay Repeated Administration Studies. Journal of Occupational Health, 2005, 47, 293-298.	1.0	65
282	Effects of a Specially Designed Fermented Milk Product Containing Probiotic Lactobacillus casei DN-114 001 and the Eradication of H. pylori in Children. Journal of Clinical Gastroenterology, 2005, 39, 692-698.	1.1	183
283	Antibiotic-Resistant Helicobacter pylori Strains in Portuguese Children. Pediatric Infectious Disease Journal, 2005, 24, 404-409.	1.1	47
284	Peptic ulcer and Helicobacter pylori. Postgraduate Medicine, 2005, 117, 17-46.	0.9	4
285	Treatment Regimens for Helicobacter pylori Infection in Children: Is In Vitro Susceptibility Testing Helpful?. Journal of Pediatric Gastroenterology and Nutrition, 2005, 40, 571-574.	0.9	36
287	The humoral immuneresponse to Helicobacter pylori infection in children with gastrointestinal symptoms. FEMS Immunology and Medical Microbiology, 2005, 44, 205-212.	2.7	18



#	ARTICLE	IF	CITATIONS
288	Improved infrared spectrophotometer for point-of-care patient 13C-urea breath testing in the primary care setting. <i>Clinical Biochemistry</i> , 2005, 38, 731-734.	0.8	13
289	Comparison of Two Management Strategies for <i>Helicobacter pylori</i> Treatment: Clinical Study and Cost-effectiveness Analysis. <i>Helicobacter</i> , 2005, 10, 22-32.	1.6	24
290	Gastroduodenal Lesions and <i>Helicobacter pylori</i> Infection in Dyspeptic Patients With and Without Chronic Renal Failure. <i>Helicobacter</i> , 2005, 10, 53-58.	1.6	37
291	Efficacy of Cranberry Juice on <i>Helicobacter pylori</i> Infection: a Double-Blind, Randomized Placebo-Controlled Trial. <i>Helicobacter</i> , 2005, 10, 139-145.	1.6	119
292	Systematic Review and Meta-analysis: Proton Pump Inhibitor vs. Ranitidine Bismuth Citrate Plus Two Antibiotics in <i>Helicobacter pylori</i> Eradication. <i>Helicobacter</i> , 2005, 10, 157-171.	1.6	66
293	<i>Helicobacter pylori</i> "Rescue" Therapy After Failure of Two Eradication Treatments. <i>Helicobacter</i> , 2005, 10, 363-372.	1.6	99
294	Alarming Clarithromycin Resistance of <i>Helicobacter pylori</i> in Turkish Population. <i>Helicobacter</i> , 2005, 10, 360-361.	1.6	24
295	Immunity Markers in Patients with <i>Helicobacter pylori</i> Infection: Effect of Eradication. <i>Helicobacter</i> , 2005, 10, 391-397.	1.6	16
296	Eradication of <i>Helicobacter pylori</i> : recent advances in treatment. <i>Fundamental and Clinical Pharmacology</i> , 2005, 19, 421-427.	1.0	29
297	Posttreatment 13C-urea breath test is predictive of antimicrobial resistance to <i>H. pylori</i> after failed therapy. <i>Journal of General Internal Medicine</i> , 2005, 20, 139-142.	1.3	15
298	Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of <i>Helicobacter pylori</i> infection. <i>Chinese Journal of Digestive Diseases</i> , 2005, 6, 202-205.	1.1	6
299	Changing trends in peptic ulcer prevalence in a tertiary care setting in the Philippines: A seven-year study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2005, 20, 628-632.	1.4	38
300	Ranitidine bismuth citrate-based triple therapies as a second-line therapy for <i>Helicobacter pylori</i> in Turkish patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2005, 20, 637-642.	1.4	6
301	Impact of <i>Helicobacter pylori</i> eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2005, 20, 1886-1891.	1.4	6
302	A combination of the <i>Helicobacter pylori</i> stool antigen test and urea breath test is useful for clinical evaluation of eradication therapy: A multicenter study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2005, 20, 1241-1245.	1.4	16
303	Probiotics and gastrointestinal diseases. <i>Journal of Internal Medicine</i> , 2005, 257, 78-92.	2.7	164
304	<i>Helicobacter pylori</i> infection in patients with haemophilia in Poland: prevalence and risk of upper gastrointestinal bleeding. <i>Haemophilia</i> , 2005, 11, 376-379.	1.0	10
305	An in vivo model for gastric physiological and pathophysiological studies in the mouse. <i>Acta Physiologica Scandinavica</i> , 2005, 184, 151-159.	2.3	13

#	ARTICLE	IF	CITATIONS
306	Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 91-96.	1.9	81
307	Standard treatment for Helicobacter pylori infection is suboptimal in non-ulcer dyspepsia compared with duodenal ulcer in Chinese. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 73-81.	1.9	24
308	Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 283-288.	1.9	80
309	Evaluation of a new rapid immunoassay for the detection of Helicobacter pylori in faeces: a prospective pilot study. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 485-489.	1.9	29
310	Is Helicobacter pylori seropositivity related to body mass index in the United States?. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 765-772.	1.9	52
311	New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 783-787.	1.9	55
312	First-line eradication therapy for Helicobacter pylori in primary health care based on antibiotic resistance: results of three eradication regimens. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 773-782.	1.9	25
313	Long-term follow-up of Helicobacter pylori eradication therapy in Vietnam: reinfection and clinical outcome. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 1047-1053.	1.9	39
314	Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 1241-1247.	1.9	61
315	Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer?. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 795-804.	1.9	61
316	Missing gastric cancer in dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 813-820.	1.9	47
317	Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy - a placebo-controlled, double-blind randomized pilot study. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 1263-1272.	1.9	183
318	Helicobacter pylori eradication does not cause reflux oesophagitis in functional dyspeptic patients: a randomized, investigator-blinded, placebo-controlled trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 1231-1239.	1.9	26
319	7-day rescue therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 1249-1253.	1.9	11
320	Long-term follow-up of Helicobacter pylori eradication therapy in Vietnam: reinfection and clinical outcome. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 76-77.	1.9	7
321	A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 45-49.	1.9	106
322	Helicobacter pylori eradication, CYP2C19 and omeprazole doses. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 273-274.	1.9	2
323	Helicobacter pylori eradication, CYP2C19 and omeprazole doses: Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 274-274.	1.9	0

#	ARTICLE	IF	CITATIONS
324	The efficacy of <i>Helicobacter pylori</i> eradication related to CYP2C19 metabolism: Author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 275-276.	1.9	2
325	Is a long-term ranitidine-based triple therapy against <i>Helicobacter pylori</i> only a heritage of the past? A prospective, randomized clinicopharmacological study. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 343-348.	1.9	0
326	Review article: the long-term use of proton-pump inhibitors. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 55-63.	1.9	141
327	Evaluation of the Ez-HBT <i>Helicobacter</i> blood test to establish <i>Helicobacter pylori</i> eradication. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 875-880.	1.9	12
328	<i>Helicobacter pylori</i> first-line treatment and rescue options in patients allergic to penicillin. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 1041-1046.	1.9	56
329	<i>Helicobacter pylori</i> Infection and Surgical Disease—Part I. <i>Current Problems in Surgery</i> , 2005, 42, 756-789.	0.6	2
330	Radiation therapy for localized low-grade non-Hodgkin's lymphomas. <i>Hematological Oncology</i> , 2005, 23, 10-17.	0.8	73
331	Prognostic significance of alarm symptoms in patients with gastric cancer (Br J Surg 2005; 92: Tj ETQq1 1 0.784314, rgBT /Oyerlock 10 0.1)	0.1	1
332	Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with <i>Helicobacter pylori</i> infection. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 375-379.	0.8	40
333	In vitro induction of resistance to metronidazole, and analysis of mutations in <i>rdxA</i> and <i>frxA</i> genes from <i>Helicobacter pylori</i> isolates. <i>Journal of Infection and Chemotherapy</i> , 2005, 11, 59-63.	0.8	18
334	In vitro activity of fosfomycin alone and in combination with amoxicillin, clarithromycin and metronidazole against <i>Helicobacter pylori</i> compared with combined clarithromycin and metronidazole. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2005, 24, 276-279.	1.3	11
335	Diagnosis and treatment of <i>Helicobacter pylori</i> . <i>Current Treatment Options in Gastroenterology</i> , 2005, 8, 163-174.	0.3	2
336	Update on therapeutic options for <i>Helicobacter pylori</i> -related diseases. <i>Current Infectious Disease Reports</i> , 2005, 7, 115-120.	1.3	25
337	<i>Helicobacter pylori</i> Infection in Patients with Erosive Esophagitis Is Associated with Rapid Heartburn Relief and Lack of Relapse After Treatment with Pantoprazole. <i>Digestive Diseases and Sciences</i> , 2005, 50, 432-439.	1.1	12
338	Twice-Daily Standard Dose of Omeprazole Achieves the Necessary Level of Acid Inhibition for <i>Helicobacter pylori</i> Eradication. A Randomized Controlled Trial Using Standard and Double Doses of Omeprazole in Triple Therapy. <i>Digestive Diseases and Sciences</i> , 2005, 50, 443-448.	1.1	24
339	Comparison of the Clinical Feasibility of Three Rapid Urease Tests in the Diagnosis of <i>Helicobacter pylori</i> Infection. <i>Digestive Diseases and Sciences</i> , 2005, 50, 449-452.	1.1	44
340	Evaluation of the Stool Antigen Test for <i>Helicobacter pylori</i> in Children and Adolescents. <i>Digestive Diseases and Sciences</i> , 2005, 50, 453-457.	1.1	31
341	High Eradication Rates of <i>Helicobacter pylori</i> Infection with First- and Second-Line Combination of Esomeprazole, Tetracycline, and Metronidazole in Patients Allergic to Penicillin. <i>Digestive Diseases and Sciences</i> , 2005, 50, 634-639.	1.1	37

#	ARTICLE	IF	CITATIONS
342	Need for Guidelines in Gastroenterology for the General Practitioner. <i>Digestive Diseases and Sciences</i> , 2005, 50, 807-808.	1.1	0
343	Influence of 1-Week <i>Helicobacter pylori</i> Eradication Therapy with Rabeprazole, Clarithromycin, and Metronidazole on 13C-Aminopyrine Breath Test. <i>Digestive Diseases and Sciences</i> , 2005, 50, 1207-1213.	1.1	15
344	13C-Urea Breath Test for Success of <i>Helicobacter pylori</i> Eradication: Study of 5885 Israeli Patients.. <i>Digestive Diseases and Sciences</i> , 2005, 50, 1513-1516.	1.1	7
345	Relevance of Adjusted Cut-off Values in Commercial Serological Immunoassays for <i>Helicobacter pylori</i> Infection in Children. <i>Digestive Diseases and Sciences</i> , 2005, 50, 2103-2109.	1.1	19
346	Survey of general practitioners' knowledge about <i>Helicobacter pylori</i> infection. <i>BMC Gastroenterology</i> , 2005, 5, 4.	0.8	15
348	A 13-Week Toxicity Study of Bismuth in Rats by Intratracheal Intermittent Administration. <i>Journal of Occupational Health</i> , 2005, 47, 242-248.	1.0	14
349	Treatment of uncomplicated reflux disease. <i>World Journal of Gastroenterology</i> , 2005, 11, 4291.	1.4	60
350	Comparison of a monoclonal antigen stool test (Hp StAR) with the 13C-urea breath test (UBT) in monitoring <i>Helicobacter pylori</i> eradication therapy. <i>World Journal of Gastroenterology</i> , 2005, 11, 5878.	1.4	15
352	Test and treat for dyspepsia— but which test?. <i>BMJ: British Medical Journal</i> , 2005, 330, 105-106.	2.4	24
353	Prevalence of <i>Helicobacter pylori</i> in Indigenous Western Australians: comparison between urban and remote rural populations. <i>Medical Journal of Australia</i> , 2005, 182, 210-213.	0.8	52
354	Sofalcone, a mucoprotective agent, increases the cure rate of <i>Helicobacter pylori</i> infection when combined with rabeprazole, amoxicillin and clarithromycin. <i>World Journal of Gastroenterology</i> , 2005, 11, 1629.	1.4	29
355	<i>Helicobacter pylori</i> infection in Indigenous Australians: a serious health issue?. <i>Medical Journal of Australia</i> , 2005, 182, 205-206.	0.8	2
356	A furazolidone-based quadruple therapy for <i>Helicobacter pylori</i> retreatment in patients with peptic ulcer disease. <i>Clinics</i> , 2005, 60, 485-8.	0.6	22
357	Efficacy of omeprazole and amoxicillin with either clarithromycin or metronidazole on eradication of <i>Helicobacter pylori</i> in Chinese peptic ulcer patients. <i>World Journal of Gastroenterology</i> , 2005, 11, 2477.	1.4	19
358	An Update on Anti- <i>Helicobacter Pylori</i> Treatment in Children. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2005, 19, 441-445.	1.8	15
359	Risk Factors Associated with the Development of Intestinal Metaplasia in First-Degree Relatives of Gastric Cancer Patients. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 2982-2986.	1.1	38
360	Seven versus Ten Days of Rabeprazole Triple Therapy for <i>Helicobacter pylori</i> Eradication: A Multicenter Randomized Trial. <i>American Journal of Gastroenterology</i> , 2005, 100, 1696-1701.	0.2	57
361	In Vitro Antimicrobial Susceptibility Testing of <i>Helicobacter felis</i> , <i>H. bizzozeronii</i> , and <i>H. salomonis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 2997-3000.	1.4	30

#	ARTICLE	IF	CITATIONS
362	Prognostic influence of Barrett's oesophagus and <i>Helicobacter pylori</i> infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study. <i>Gut</i> , 2005, 54, 746-751.	6.1	86
363	Evaluation of Antibiotic Treatment against <i>Helicobacter suis</i> in a Mouse Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 4530-4535.	1.4	14
364	Bactericidal and Morphological Effects of NE-2001, a Novel Synthetic Agent Directed against <i>Helicobacter pylori</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3468-3473.	1.4	18
365	The leucyl aminopeptidase from <i>Helicobacter pylori</i> is an allosteric enzyme. <i>Microbiology (United Kingdom)</i> 151: 107-114 (2005)	0.7	29
366	16 Role of <i>Helicobacter pylori</i> in Gastric Cancer. <i>Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas</i> , 2005, 4, 205-220.	0.0	0
367	Real-time PCR detection and frequency of 16S rDNA mutations associated with resistance and reduced susceptibility to tetracycline in <i>Helicobacter pylori</i> from England and Wales. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 282-286.	1.3	43
368	How effective are quadruple therapies as first-line <i>H. pylori</i> eradication therapies?. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2005, 2, 174-175.	1.7	1
369	How effective are rescue <i>H. pylori</i> eradication therapies in patients with dyspepsia?. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2005, 2, 180-181.	1.7	0
370	Does <i>H. Pylori</i> Infection Play a Role in Idiopathic Thrombocytopenic Purpura and in Other Autoimmune Diseases?. <i>American Journal of Gastroenterology</i> , 2005, 100, 1271-1273.	0.2	29
371	<i>Helicobacter pylori</i> : Factors Affecting Eradication and Recurrence. <i>American Journal of Gastroenterology</i> , 2005, 100, 2393-2394.	0.2	15
372	<i>Helicobacter pylori</i> Eradication Has the Potential to Prevent Gastric Cancer: A State-of-the-Art Critique. <i>American Journal of Gastroenterology</i> , 2005, 100, 2100-2115.	0.2	202
373	The Recurrence of <i>Helicobacter pylori</i> Infection: Incidence and Variables Influencing It. A Critical Review. <i>American Journal of Gastroenterology</i> , 2005, 100, 2083-2099.	0.2	107
374	Esomeprazole-Based Therapy in <i>Helicobacter pylori</i> Eradication: Any Effect by Increasing the Dose of Esomeprazole or Prolonging the Treatment?. <i>American Journal of Gastroenterology</i> , 2005, 100, 1935-1940.	0.2	34
375	Evaluation of a Novel Rapid One-Step Immunochromatographic Assay for Detection of Monoclonal <i>Helicobacter pylori</i> Antigen in Stool Samples from Children. <i>Journal of Clinical Microbiology</i> , 2005, 43, 2598-2601.	1.8	39
376	The interplay between <i>Helicobacter pylori</i> , gastro-oesophageal reflux disease, and intestinal metaplasia. <i>Gut</i> , 2005, 54, i13-i20.	6.1	53
377	<i>Lactobacillus johnsonii</i> La1 Attenuates <i>Helicobacter pylori</i> -Associated Gastritis and Reduces Levels of Proinflammatory Chemokines in C57BL/6 Mice. <i>Vaccine Journal</i> , 2005, 12, 1378-1386.	3.2	84
378	Best practice in primary care pathology: review 1. <i>Journal of Clinical Pathology</i> , 2005, 58, 1016-1024.	1.0	31
379	<i>Helicobacter Pylori</i> Infection Causes Persistent Platelet Activation In Vivo Through Enhanced Lipid Peroxidation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 246-251.	1.1	33

#	ARTICLE	IF	CITATIONS
380	Evaluation of two enzyme immunoassays for detecting <i>Helicobacter pylori</i> in stool specimens of dyspeptic patients after eradication therapy. <i>Journal of Medical Microbiology</i> , 2005, 54, 863-866.	0.7	24
381	Use of Proton Pump Inhibitors: An Exploration of the Attitudes, Knowledge and Perceptions of General Practitioners. <i>Digestion</i> , 2005, 72, 212-218.	1.2	20
382	Eradication of <i>Helicobacter pylori</i> Can Be Accurately Confirmed 14 Days after Termination of Triple Therapy Using a High-Dose Citric Acid-Based <sup>13</sup> C Urea Breath Test. <i>Digestion</i> , 2005, 71, 208-212.	1.2	17
383	Effectiveness of Antiinfectives. <i>Chemotherapy</i> , 2005, 51, 243-246.	0.8	8
384	Real-Time PCR Screening for 16S rRNA Mutations Associated with Resistance to Tetracycline in <i>Helicobacter pylori</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3166-3170.	1.4	49
385	Effect of regular ingestion of <i>Saccharomyces boulardii</i> plus inulin or <i>Lactobacillus acidophilus</i> LB in children colonized by <i>Helicobacter pylori</i> . <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2005, 94, 1747-1751.	0.7	12
386	<i>Helicobacter pylori</i> antibiotic-resistance patterns and risk factors in adult dyspeptic patients from ethnically diverse populations in central and south London during 2000. <i>Journal of Medical Microbiology</i> , 2005, 54, 567-574.	0.7	22
387	What Is New Related to <i>Helicobacter pylori</i> Infection in Children and Teenagers?. <i>JAMA Pediatrics</i> , 2005, 159, 415.	3.6	45
388	Vaccination as a Method of Preventing <i>Helicobacter pylori</i> -Associated Gastric Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1890-1891.	1.1	17
389	The optimal age threshold for screening upper endoscopy for uninvestigated dyspepsia in Taiwan, an area with a higher prevalence of gastric cancer in young adults. <i>Gastrointestinal Endoscopy</i> , 2005, 61, 819-825.	0.5	44
390	The effects of eradication of <i>Helicobacter pylori</i> on the recurrence of duodenal ulcers in patients with cirrhosis. <i>Gastrointestinal Endoscopy</i> , 2005, 62, 350-356.	0.5	43
391	$\beta$ -Lactamase inhibition with clavulanic acid supplementing standard amoxicillin-based triple therapy does not increase eradication rate. <i>Digestive and Liver Disease</i> , 2005, 37, 826-831.	0.4	7
392	A Prospective Randomized Trial of Esomeprazole- versus Pantoprazole-Based Triple Therapy for <i>Helicobacter pylori</i> Eradication. <i>American Journal of Gastroenterology</i> , 2005, 100, 2387-2392.	0.2	62
393	Comparison of different protocols for <sup>13</sup> C-urea breath test for the diagnosis of <i>Helicobacter pylori</i> infection in healthy volunteers. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2005, 65, 491-498.	0.6	17
394	Comparison of three stool antigen tests in confirming <i>Helicobacter pylori</i> eradication in adults. <i>Scandinavian Journal of Gastroenterology</i> , 2005, 40, 395-401.	0.6	30
395	Efficacy of a Low-Dose Omeprazole-Based Triple-Therapy Regimen for <i>Helicobacter pylori</i> Eradication Independent of Cytochrome P450 Genotype. <i>Clinical Drug Investigation</i> , 2005, 25, 293-305.	1.1	19
396	Nonulcer dyspepsia and <i>Helicobacter pylori</i> eradication in children. <i>Journal of Pediatric Surgery</i> , 2005, 40, 1547-1550.	0.8	11
397	Tinidazole: A nitroimidazole antiprotozoal agent. <i>Clinical Therapeutics</i> , 2005, 27, 1859-1884.	1.1	122

#	ARTICLE	IF	CITATIONS
402	Important Bacterial Gastrointestinal Pathogens in Children: A Pathogenesis Perspective. <i>Pediatric Clinics of North America</i> , 2005, 52, 749-777.	0.9	36
404	Diagnosing <i>Helicobacter pylori</i> In Vivo by Confocal Laser Endoscopy. <i>Gastroenterology</i> , 2005, 128, 2119-2123.	0.6	165
405	<i>Helicobacter pylori</i> Test and Treatment or Endoscopy for Managing Dyspepsia: An Individual Patient Data Meta-analysis. <i>Gastroenterology</i> , 2005, 128, 1838-1844.	0.6	122
406	Improved Efficacy of 10-Day Sequential Treatment for <i>Helicobacter pylori</i> Eradication in Children: A Randomized Trial. <i>Gastroenterology</i> , 2005, 129, 1414-1419.	0.6	134
407	American Gastroenterological Association Technical Review on the Evaluation of Dyspepsia. <i>Gastroenterology</i> , 2005, 129, 1756-1780.	0.6	368
408	Antibiotic resistance of <i>Helicobacter pylori</i> isolated in Split, Southern Croatia. <i>International Journal of Antimicrobial Agents</i> , 2005, 25, 449-450.	1.1	8
409	HpSA fecoprevalence in patients suspected to have <i>Helicobacter pylori</i> infection in Istanbul, Turkey. <i>International Journal of Infectious Diseases</i> , 2005, 9, 21-26.	1.5	11
410	Rifabutin based triple therapy for eradication of <i>H. pylori</i> primary and secondary resistant to tinidazole and clarithromycin. <i>Digestive and Liver Disease</i> , 2005, 37, 33-38.	0.4	52
411	Clinical usefulness of serum pepsinogens I and II, gastrin-17 and anti- <i>Helicobacter pylori</i> antibodies in the management of dyspeptic patients in primary care. <i>Digestive and Liver Disease</i> , 2005, 37, 501-508.	0.4	63
412	Quadruple therapy with lactoferrin for <i>Helicobacter pylori</i> eradication: A randomised, multicentre study. <i>Digestive and Liver Disease</i> , 2005, 37, 496-500.	0.4	39
413	Antisecretory drugs, <i>Helicobacter pylori</i> infection and symptom relief in GORD: Still an unexplored triangle. <i>Digestive and Liver Disease</i> , 2005, 37, 468-474.	0.4	10
414	One-week once-daily triple therapy with esomeprazole, levofloxacin and azithromycin compared to a standard therapy for <i>Helicobacter pylori</i> eradication. <i>Digestive and Liver Disease</i> , 2005, 37, 571-576.	0.4	28
415	<sup>13</sup> C-urea breath test in the management of <i>Helicobacter pylori</i> infection. <i>Digestive and Liver Disease</i> , 2005, 37, 899-906.	0.4	38
416	Reflux gastro-œsophagien chez l'enfant. <i>EMC - Pédiatrie</i> , 2005, 2, 196-209.	0.0	2
417	Guidelines for the Management of Dyspepsia. <i>American Journal of Gastroenterology</i> , 2005, 100, 2324-2337.	0.2	411
418	Reflujo gastroesofágico en el niño. <i>EMC Pediatría</i> , 2005, 40, 1-11.	0.0	0
419	Maintenance Therapy in Gastro-oesophageal Reflux Disease. <i>Drugs</i> , 2005, 65, 59-66.	4.9	5
420	Rabeprazole: the role of proton pump inhibitors in <i>Helicobacter pylori</i> eradication. <i>Expert Review of Anti-Infective Therapy</i> , 2005, 3, 863-870.	2.0	14

#	ARTICLE	IF	CITATIONS
421	Acid Suppression Therapy: Where Do We Go from Here?. <i>Digestive Diseases</i> , 2006, 24, 11-46.	0.8	87
422	Effects of <i>Helicobacter pylori</i> and Nonsteroidal Anti-Inflammatory Drugs on Peptic Ulcer Disease: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 130-142.	2.4	124
423	Faecal antigen tests in the confirmation of the effect of <i>Helicobacter</i> eradication therapy. <i>Annals of Medicine</i> , 2006, 38, 352-356.	1.5	7
424	Non-steroidal anti-inflammatory drugs request parity with <i>Helicobacter pylori</i> . <i>Scandinavian Journal of Gastroenterology</i> , 2006, 41, 373-375.	0.6	4
425	<i>Helicobacter pylori</i> infection in 1st degree relatives of Chinese gastric cancer patients. <i>Scandinavian Journal of Gastroenterology</i> , 2006, 41, 274-279.	0.6	22
426	<i>Helicobacter pylori</i> and antimicrobial resistance: molecular mechanisms and clinical implications. <i>Lancet Infectious Diseases</i> , The, 2006, 6, 699-709.	4.6	268
428	Molecular subtyping of gastric MALT lymphomas: implications for prognosis and management. <i>Gut</i> , 2006, 55, 886-893.	6.1	67
429	<i>Helicobacter pylori</i> therapy: what is coming?. <i>Expert Opinion on Therapeutic Patents</i> , 2006, 16, 1107-1112.	2.4	7
430	Antibiotic Therapy for <i>Helicobacter pylori</i> . <i>Medical Clinics of North America</i> , 2006, 90, 1125-1140.	1.1	9
431	Functional Gastrointestinal Disorders. <i>Gastroenterology</i> , 2006, 130, 1466-1479.	0.6	1,740
432	Eradication therapy for peptic ulcer disease in <i>Helicobacter pylori</i> positive patients. , 2006, , CD003840.		85
434	Is there any correlation between <sup>13</sup> C-urea breath test values and response to first-line and rescue <i>Helicobacter pylori</i> eradication therapies?. <i>Digestive and Liver Disease</i> , 2006, 38, 254-259.	0.4	11
435	<i>Helicobacter pylori</i> eradication: How can I choose an appropriate therapy?. <i>Digestive and Liver Disease</i> , 2006, 38, 259-261.	0.4	0
436	Acid-suppressive effects of rabeprazole: Comparing 10mg and 20mg twice daily in Japanese <i>Helicobacter pylori</i> -negative and -positive CYP2C19 extensive metabolisers. <i>Digestive and Liver Disease</i> , 2006, 38, 802-808.	0.4	23
437	Point-of-care <i>Helicobacter pylori</i> urine antibody detection in a multi-ethnic adult population in the United States. <i>Translational Research</i> , 2006, 148, 13-18.	2.2	13
438	Levofloxacin-Based Triple Therapy versus Bismuth-Based Quadruple Therapy for Persistent <i>Helicobacter pylori</i> Infection: A Meta-Analysis. <i>CME. American Journal of Gastroenterology</i> , 2006, 101, 488-496.	0.2	239
439	Mechanisms of Disease: <i>Helicobacter pylori</i> -related gastric carcinogenesis—implications for chemoprevention. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2006, 3, 622-632.	1.7	65
440	Eradication of <i>Helicobacter pylori</i> with triple therapy: An epidemiologic analysis of trends in Turkey over 10 years. <i>Clinical Therapeutics</i> , 2006, 28, 1960-1966.	1.1	73



#	ARTICLE	IF	CITATIONS
441	Quality of life in patients with functional dyspepsia: Short- and long-term effect of <i>Helicobacter pylori</i> eradication with pantoprazole, amoxicillin, and clarithromycin or cisapride therapy: A prospective, parallel-group study. <i>Current Therapeutic Research</i> , 2006, 67, 305-320.	0.5	9
442	The clinical applications and accuracy of 2 rapid near-patient tests in detecting <i>Helicobacter pylori</i> infection. <i>Diagnostic Microbiology and Infectious Disease</i> , 2006, 56, 241-246.	0.8	11
443	Comparison of stool enzyme immunoassay and immunochromatographic method for detecting <i>Helicobacter pylori</i> antigens before and after eradication. <i>Diagnostic Microbiology and Infectious Disease</i> , 2006, 56, 373-378.	0.8	19
445	Protective immunization against <i>Candidatus Helicobacter suis</i> with heterologous antigens of <i>H. pylori</i> and <i>H. felis</i> . <i>Vaccine</i> , 2006, 24, 2469-2476.	1.7	2
446	Efficacy of Two Triple Eradication Regimens in Children with <i>Helicobacter pylori</i> Infection. <i>Journal of Korean Medical Science</i> , 2006, 21, 1037.	1.1	13
447	<sup>13</sup> C Urea Breath Test for <i>Helicobacter pylori</i> : Determination of the Optimal Cut-Off Point in a Canadian Community Population. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2006, 20, 770-774.	1.8	18
448	<i>Helicobacter pylori</i> Eradication with Either Seven-Day or 10-Day Triple Therapies, and with a 10-Day Sequential Regimen. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2006, 20, 113-117.	1.8	74
449	The Association of <i>Helicobacter pylori</i> Infection and Nonsteroidal Anti-Inflammatory Drugs in Peptic Ulcer Disease. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2006, 20, 277-280.	1.8	53
450	<sup>13</sup> C Urea Breath Test for <i>Helicobacter pylori</i> : Evaluation of 10-minute Breath Collection. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2006, 20, 775-778.	1.8	9
453	Pretreatment with Lactobacillus- and Bifidobacterium-containing yogurt can improve the efficacy of quadruple therapy in eradicating residual <i>Helicobacter pylori</i> infection after failed triple therapy. <i>American Journal of Clinical Nutrition</i> , 2006, 83, 864-869.	2.2	126
455	Evaluation of Four Different Fecal Tests for Determination of Cure After <i>Helicobacter pylori</i> Treatment. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 790-794.	1.1	16
457	Can <i>Helicobacter pylori</i> Eradication Regimens be Shortened in Clinical Practice? An Open-label, Randomized, Pilot Study of 4 and 7-day Triple Therapy With Rabeprazole, High-dose Levofloxacin, and Tinidazole. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 515-520.	1.1	16
458	Evaluation of triple and quadruple <i>Helicobacter pylori</i> eradication therapies in Iranian children: a randomized clinical trial. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 511-514.	0.8	22
459	Comparison of three stool antigen assays with the <sup>13</sup> C urea breath test for the primary diagnosis of <i>Helicobacter pylori</i> infection and monitoring treatment outcome. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 595-599.	0.8	29
460	Early diagnosis of early gastric cancer. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 821-829.	0.8	95
463	Clinical Trial Evaluating Amoxicillin and Clarithromycin Hydrogels (Chitosan-polyacrylic Acid) Tj ETQq1 1 0.784314 rgBT /Overlock 10 TFS	0.8	23
464	Institutional Difference of Antibiotic Resistance of <i>Helicobacter pylori</i> Strains in Korea. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 683-687.	1.1	96
465	Gastric epithelial cell proliferation and ras oncogene p21 expression in first-degree relatives of gastric cancer patients: a case-control study. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 921-926.	0.8	3

#	ARTICLE	IF	CITATIONS
466	Follow-Up Care After a Diagnosis of <i>Helicobacter pylori</i> Infection in an Asian Immigrant Cohort. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 29-32.	1.1	5
467	Maintenance therapy with H2-receptor antagonist until assessment of <i>Helicobacter pylori</i> eradication can reduce recurrence of peptic ulcer after successful eradication of the organism: prospective randomized controlled trial. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 1048-1053.	1.4	5
468	Tetracycline, metronidazole and amoxicillin-metronidazole combinations in proton pump inhibitor-based triple therapies are equally effective as alternative therapies against <i>Helicobacter pylori</i> infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 232-236.	1.4	20
469	Combinations containing amoxicillin-clavulanate and tetracycline are inappropriate for <i>Helicobacter pylori</i> eradication despite high in vitro susceptibility. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 1590-1595.	1.4	10
470	HELICOBACTER PYLORI INFECTION AND TREATMENT OUTCOME IN AN URBAN AUSTRALIAN POPULATION. ANZ <i>Journal of Surgery</i> , 2006, 76, 710-714.	0.3	7
471	In vitro growth inhibition of <i>Helicobacter pylori</i> by lactobacilli belonging to the <i>Lactobacillus plantarum</i> group. <i>Letters in Applied Microbiology</i> , 2006, 43, 508-513.	1.0	34
472	Consequences of Long-Term Proton Pump Blockade: Insights from Studies of Patients with Gastrinomas. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2006, 98, 4-19.	1.2	118
473	Randomized comparison of two rescue therapies for <i>Helicobacter pylori</i> infection. <i>European Journal of Clinical Investigation</i> , 2006, 36, 803-809.	1.7	32
474	Usefulness of a delayed test for the diagnosis of <i>Helicobacter pylori</i> infection in bleeding peptic ulcer. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 53-59.	1.9	33
475	Systematic review and meta-analysis: levofloxacin-based rescue regimens after <i>Helicobacter pylori</i> treatment failure. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 35-44.	1.9	296
476	Rabeprazole containing triple therapy to eradicate <i>Helicobacter pylori</i> infection on the Texas-Mexican border. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 295-301.	1.9	11
477	A study of 4- and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for <i>Helicobacter pylori</i> eradication. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 281-287.	1.9	22
478	Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 421-427.	1.9	53
479	Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 481-488.	1.9	80
480	Clinical and endoscopic presentation of primary gastric lymphoma: a multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 721-726.	1.9	51
481	Recurrence of <i>Helicobacter pylori</i> infection after several eradication therapies: long-term follow-up of 1000 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 713-719.	1.9	45
482	Bovine lactoferrin for <i>Helicobacter pylori</i> eradication: an open, randomized, multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 1235-1240.	1.9	43
483	Review article: the opportunities and benefits of extended acid suppression. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 23-34.	1.9	34

#	ARTICLE	IF	CITATIONS
484	Seven-day is more effective than 4-day ranitidine bismuth citrate-based triple therapy in eradication of <i>Helicobacter pylori</i> in children: a prospective randomized study. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 81-86.	1.9	19
485	Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of <i>Helicobacter pylori</i> resistant to both metronidazole and clarithromycin. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 395-403.	1.9	78
486	The <sup>13</sup> C-urea breath test for the diagnosis of <i>Helicobacter pylori</i> infection in subjects with atrophic gastritis: evaluation in a primary care setting. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 643-650.	1.9	14
487	Impact of <i>Helicobacter pylori</i> on the management of dyspepsia in primary care. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 637-641.	1.9	14
488	Sequential therapy using high-dose esomeprazole-amoxicillin followed by gatifloxacin for <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 845-850.	1.9	36
489	Corpus-predominant gastritis as a risk factor for false-negative <sup>13</sup> C-urea breath test results. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 1453-1460.	1.9	26
490	<i>Lactobacillus reuteri</i> therapy to reduce side-effects during anti- <i>Helicobacter pylori</i> treatment in children: a randomized placebo controlled trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 1461-1468.	1.9	155
491	Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two <i>Helicobacter pylori</i> treatment failures. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 1469-1474.	1.9	81
492	Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during <i>Helicobacter pylori</i> eradication therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 155-168.	1.9	214
493	Systematic review: <i>Helicobacter pylori</i> eradication for the prevention of gastric cancer. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 133-141.	1.9	99
494	<i>Helicobacter pylori</i> eradication in long-term proton pump inhibitor users in primary care: a randomized controlled trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 585-592.	1.9	14
495	Can gastric cancer be prevented by <i>Helicobacter pylori</i> eradication?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2006, 20, 709-719.	1.0	24
496	Twice-A-Day Quadruple Therapy for Eradication of <i>Helicobacter pylori</i> in the Elderly. <i>Helicobacter</i> , 2006, 11, 52-55.	1.6	24
497	Efficacy of Moxifloxacin-Based Triple Therapy as Second-Line Treatment for <i>Helicobacter pylori</i> Infection. <i>Helicobacter</i> , 2006, 11, 46-51.	1.6	53
498	7-Day Triple Therapy of <i>Helicobacter pylori</i> Infection with Levofloxacin, Amoxicillin, and High-Dose Esomeprazole in Patients with Known Antimicrobial Sensitivity. <i>Helicobacter</i> , 2006, 11, 39-45.	1.6	74
499	Treatment of <i>Helicobacter pylori</i> Infection. <i>Helicobacter</i> , 2006, 11, 36-39.	1.6	35
500	Multiple Mutations in or Adjacent to the Conserved Penicillin-Binding Protein Motifs of the Penicillin-Binding Protein 1A Confer Amoxicillin Resistance to <i>Helicobacter pylori</i> . <i>Helicobacter</i> , 2006, 11, 181-187.	1.6	65
501	Evolution of the Management of <i>Helicobacter pylori</i> Infection in General Practice. <i>Helicobacter</i> , 2006, 11, 208-210.	1.6	2

#	ARTICLE	IF	CITATIONS
502	Bioinformatic Analysis of Helicobacter pylori XGPRTase: A Potential Therapeutic Target. Helicobacter, 2006, 11, 287-295.	1.6	11
503	Antimicrobial Susceptibility of Helicobacter pylori Strains in a Random Adult Swedish Population. Helicobacter, 2006, 11, 224-230.	1.6	34
504	Primary Levofloxacin Resistance and gyrA/B Mutations Among Helicobacter pylori in Japan. Helicobacter, 2006, 11, 243-249.	1.6	120
505	A Community-Based Study of Helicobacter pylori Therapy Using the Strategy of Test, Treat, Retest, and Re-treat Initial Treatment Failures. Helicobacter, 2006, 11, 418-424.	1.6	45
506	Helicobacter pylori Recurrence in Patients with Duodenal Ulcer: Clinical, Endoscopic, Histologic, and Genotypic Aspects. A 10-Year Brazilian Series. Helicobacter, 2006, 11, 431-435.	1.6	9
507	Prevalence and Mechanisms of Resistance to Fluoroquinolones in Helicobacter pylori Strains from Patients Living in Belgium. Helicobacter, 2006, 11, 441-445.	1.6	77
508	2-Week Triple Therapy for Helicobacter pylori Infection is Better Than 1-Week in Clinical Practice: a Large Prospective Single-Center Randomized Study. Helicobacter, 2006, 11, 562-568.	1.6	70
509	Susceptibility-Guided vs. Empiric Retreatment of Helicobacter pylori Infection After Treatment Failure. Digestive Diseases and Sciences, 2006, 51, 2316-2321.	1.1	28
515	Les gastrites: comment r��agir devant une gastrite ? Aspect endoscopique et corr��lation histologique. Acta Endoscopica, 2006, 36, 471-472.	0.0	0
517	Comparison of a new office-based stool immunoassay and 13C-UBT in the diagnosis of current Helicobacter pylori infection. Translational Research, 2006, 147, 145-149.	2.4	14
518	Risk assessment in relatives of gastric cancer patients: hyperproliferation, genetics, and Helicobacter pylori infection. European Journal of Gastroenterology and Hepatology, 2006, 18, 877-879.	0.8	6
519	Rifaximin-Based Regimens for Eradication of Helicobacter pylori: A Pilot Study. Digestive Diseases, 2006, 24, 195-200.	0.8	25
520	Helicobacter pylori occurrence and transmission: A family affair?. Scandinavian Journal of Infectious Diseases, 2006, 38, 407-417.	1.5	89
521	Quality Indicators for Colonoscopy. American Journal of Gastroenterology, 2006, 101, 873-885.	0.2	703
522	Impaired mucus-bicarbonate barrier in Helicobacter pylori-infected mice. American Journal of Physiology - Renal Physiology, 2006, 291, G396-G403.	1.6	33
523	Rescue Therapies for the Management of Helicobacter pylori Infection. Digestive Diseases, 2006, 24, 113-130.	0.8	49
524	Rapid detection of clarithromycin resistance in Helicobacter pylori using a PCR-based denaturing HPLC assay. Journal of Antimicrobial Chemotherapy, 2006, 57, 71-78.	1.3	22
525	Economic evaluation of empirical antisecretory therapy versus Helicobacter pylori for management of dyspepsia: A randomized trial in primary care. International Journal of Technology Assessment in Health Care, 2006, 22, 362-371.	0.2	11

#	ARTICLE	IF	CITATIONS
526	<i>Helicobacter pylori</i> Infection: Treatment Options. <i>Digestion</i> , 2006, 73, 119-128.	1.2	15
527	Shift work increases the frequency of duodenal ulcer in <i>H. pylori</i> infected workers. <i>Occupational and Environmental Medicine</i> , 2006, 63, 773-775.	1.3	49
528	Peptic ulcer disease today. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2006, 3, 80-89.	1.7	169
529	Accuracy of <i>Helicobacter pylori</i> Diagnostic Tests in Patients with Bleeding Peptic Ulcer: A Systematic Review and Meta-analysis. <i>American Journal of Gastroenterology</i> , 2006, 101, 848-863.	0.2	190
530	The treatment of <i>Helicobacter pylori</i> infection: the changing picture of a still unresolved problem. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 991-994.	1.9	0
531	Western Blotting of Total Lysate of <i>Helicobacter pylori</i> in Cases of Atrophic Body Gastritis. <i>Clinical Chemistry</i> , 2006, 52, 220-226.	1.5	22
532	Primer: managing NSAID-induced ulcer complications—balancing gastrointestinal and cardiovascular risks. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2006, 3, 563-573.	1.7	67
533	Accuracy of Monoclonal Stool Antigen Test for the Diagnosis of <i>H. pylori</i> Infection: A Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2006, 101, 1921-1930.	0.2	250
534	Levofloxacin-Based Triple Therapy in First-Line Treatment for <i>Helicobacter pylori</i> Eradication. <i>American Journal of Gastroenterology</i> , 2006, 101, 1985-1990.	0.2	67
535	Triple Levofloxacin-Based Rescue Therapy is an Accepted Empirical Third-Line Treatment. <i>American Journal of Gastroenterology</i> , 2006, 101, 1938-1938.	0.2	5
536	Third-Line Rescue Therapy with Levofloxacin After Two <i>H. pylori</i> Treatment Failures. <i>American Journal of Gastroenterology</i> , 2006, 101, 243-247.	0.2	98
537	Effective regimens for the treatment of <i>Helicobacter pylori</i> infection. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 995-1016.	1.9	21
538	Accuracy of breath tests using low doses of <sup>13</sup> C-urea to diagnose <i>Helicobacter pylori</i> infection: a randomised controlled trial. <i>Gut</i> , 2006, 55, 457-462.	6.1	44
539	Novel targets against <i>Helicobacter pylori</i> : a bioinformatic approach. <i>Future Microbiology</i> , 2007, 2, 111-114.	1.0	4
540	Detection of mixed clarithromycin-resistant and -susceptible <i>Helicobacter pylori</i> using nested PCR and direct sequencing of DNA extracted from faeces. <i>Journal of Medical Microbiology</i> , 2007, 56, 1174-1180.	0.7	60
541	The Impact of Body Mass Index on the Application of On-Demand Therapy for Los Angeles Grades A and B Reflux Esophagitis. <i>American Journal of Gastroenterology</i> , 2007, 102, 2387-2394.	0.2	32
542	Initial Treatment With Lansoprazole in Young Dyspeptic Patients With Negative Urea Breath Test Result: A Randomized Controlled Trial With 12-Month Follow-Up. <i>American Journal of Gastroenterology</i> , 2007, 102, 1483-1488.	0.2	11
543	<i>Helicobacter pylori</i> Eradication: A Randomized Prospective Study of Triple Therapy Versus Triple Therapy Plus Lactoferrin and Probiotics. <i>American Journal of Gastroenterology</i> , 2007, 102, 951-956.	0.2	134

#	ARTICLE	IF	CITATIONS
544	Comparison of two invasive diagnostic tests for <i>Helicobacter pylori</i> after antimicrobial therapy. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 330-332.	0.6	9
545	<i>Helicobacter pylori</i> and antibiotic resistance. <i>Gut</i> , 2007, 56, 1502-1502.	6.1	94
546	Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for <i>Helicobacter pylori</i> eradication: the HYPER Study. <i>Gut</i> , 2007, 56, 475-479.	6.1	82
547	How to Proceed in <i>Helicobacter pylori</i>-Positive Chronic Gastritis Refractory to First- and Second-Line Eradication Therapy. <i>Digestive Diseases</i> , 2007, 25, 203-205.	0.8	6
548	Usefulness of a Serological Panel Test in the Assessment of Gastritis in Symptomatic Children. <i>Digestive Diseases</i> , 2007, 25, 206-213.	0.8	31
549	How to manage the difficult-to-treat dyspeptic patient. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2007, 4, 35-42.	1.7	15
550	Detection rate of <i>Helicobacter pylori</i> stool antigen in newborn infants and small children. <i>Journal of Perinatal Medicine</i> , 2007, 35, 155-8.	0.6	17
551	Evaluation of the Novel <i>Helicobacter pylori</i> ClariRes Real-Time PCR Assay for Detection and Clarithromycin Susceptibility Testing of <i>H. pylori</i> in Stool Specimens from Symptomatic Children. <i>Journal of Clinical Microbiology</i> , 2007, 45, 1718-1722.	1.8	69
552	Cost-effectiveness Analysis between Primary and Secondary Preventive Strategies for Gastric Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 875-885.	1.1	76
553	Influence of smoking and CYP2C19 genotypes on <i>H. pylori</i> eradication success. <i>Epidemiology and Infection</i> , 2007, 135, 171-176.	1.0	22
554	Quantitative Correlation of <i>Helicobacter pylori</i> Stool Antigen (HpSA) Test with the Severity of <i>H. pylori</i> -Related Gastritis. <i>Tohoku Journal of Experimental Medicine</i> , 2007, 212, 159-167.	0.5	7
555	Meta-analysis: Duration of First-Line Proton-Pump Inhibitor-Based Triple Therapy for <i>Helicobacter pylori</i> Eradication. <i>Annals of Internal Medicine</i> , 2007, 147, 553.	2.0	220
557	Genetic Methods for Detecting Bacterial Resistance Genes. , 2007, , 183-227.		0
558	<i>Helicobacter pylori</i> and Probiotics1. <i>Journal of Nutrition</i> , 2007, 137, 812S-818S.	1.3	209
560	Antibiotic Treatment Strategies for <i>Helicobacter pylori</i> Infection. <i>Recent Patents on Anti-infective Drug Discovery</i> , 2007, 2, 11-17.	0.5	22
561	High <i>Helicobacter pylori</i> Resistance Rate to Clarithromycin in Turkey. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, 747-750.	1.1	36
562	Implications of Oral <i>Helicobacter pylori</i> for the Outcome of its Gastric Eradication Therapy. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, 145-151.	1.1	37
564	Comparison of 1- and 2-week pantoprazole-based triple therapies in clarithromycin-sensitive and resistant cases. <i>European Journal of Internal Medicine</i> , 2007, 18, 496-500.	1.0	11

#	ARTICLE	IF	CITATIONS
565	Non-invasive assessment of chronic liver and gastric diseases. <i>Clinica Chimica Acta</i> , 2007, 381, 39-49.	0.5	18
566	American College of Gastroenterology Guideline on the Management of <i>Helicobacter pylori</i> Infection. <i>American Journal of Gastroenterology</i> , 2007, 102, 1808-1825.	0.2	1,171
567	Effect of <i>Bifidobacterium bifidum</i> Fermented Milk on <i>Helicobacter pylori</i> and Serum Pepsinogen Levels in Humans. <i>Journal of Dairy Science</i> , 2007, 90, 2630-2640.	1.4	49
568	Current concepts in the management of <i>Helicobacter pylori</i> infection: the Maastricht III Consensus Report. <i>Gut</i> , 2007, 56, 772-781.	6.1	1,706
569	Current management of <i>Helicobacter pylori</i> infections in the elderly. <i>Expert Review of Anti-Infective Therapy</i> , 2007, 5, 845-856.	2.0	19
570	Quinolone Resistance in <i>Helicobacter pylori</i> Isolates in Germany. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 346-349.	1.4	80
571	The sequential therapy regimen for <i>Helicobacter pylori</i> eradication: a pooled-data analysis. <i>Gut</i> , 2007, 56, 1353-1357.	6.1	254
572	Treatment strategy to eradicate <i>Helicobacter pylori</i> infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2701-2717.	0.9	27
573	Characterization of rifampicin-resistant clinical <i>Helicobacter pylori</i> isolates from Germany. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 874-879.	1.3	54
575	â€œCervia II Working Group Report 2006â€ Guidelines on diagnosis and treatment of <i>Helicobacter pylori</i> infection in Italy. <i>Digestive and Liver Disease</i> , 2007, 39, 782-789.	0.4	88
576	<sup>13</sup> C-breath tests: Current state of the art and future directions. <i>Digestive and Liver Disease</i> , 2007, 39, 795-805.	0.4	112
577	Effects of anti- <i>Helicobacter pylori</i> treatment and probiotic supplementation on intestinal microbiota. <i>International Journal of Antimicrobial Agents</i> , 2007, 29, 66-72.	1.1	85
578	Update on fluoroquinolone resistance in <i>Helicobacter pylori</i> : new mutations leading to resistance and first description of a <i>gyrA</i> polymorphism associated with hypersusceptibility. <i>International Journal of Antimicrobial Agents</i> , 2007, 29, 389-396.	1.1	90
579	A Meta-Analysis of the Success Rate of <i>Helicobacter pylori</i> Therapy in Canada. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2007, 21, 295-300.	1.8	22
580	Diet, <i>H pylori</i> infection and gastric cancer: Evidence and controversies. <i>World Journal of Gastroenterology</i> , 2007, 13, 2901.	1.4	50
581	Carbonic anhydrase inhibitors: The $\hat{1}^2$ -carbonic anhydrase from <i>Helicobacter pylori</i> is a new target for sulfonamide and sulfamate inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 3585-3594.	1.0	157
582	Diagnosis of <i>Helicobacter pylori</i> : Invasive and non-invasive tests. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2007, 21, 299-313.	1.0	178
583	Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate <i>helicobacter pylori</i> infection. <i>BMC Gastroenterology</i> , 2007, 7, 31.	0.8	35

#	ARTICLE	IF	CITATIONS
584	Pharmacogenomics-based Tailored Versus Standard Therapeutic Regimen for Eradication of <i>H. pylori</i> . <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 521-528.	2.3	167
585	Evaluation of the monoclonal stool antigen test for <i>Helicobacter pylori</i> in an Asian population with dyspepsia. <i>Journal of Digestive Diseases</i> , 2007, 8, 207-210.	0.7	9
586	The efficacy of bismuth containing quadruple therapy as a first-line treatment option for <i>Helicobacter pylori</i> . <i>Journal of Digestive Diseases</i> , 2007, 8, 211-215.	0.7	40
587	Efficacy of rifabutin-based triple therapy in <i>Helicobacter pylori</i> infected patients after two standard treatments. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 60-63.	1.4	28
588	Modified allele-specific primerâ€“polymerase chain reaction method for analysis of susceptibility of <i>Helicobacter pylori</i> strains to clarithromycin. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 1810-1815.	1.4	29
589	Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate <i>Helicobacter pylori</i> with a 14-day standard first-line therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 23, 070607044750002-???	1.4	33
590	One-week versus two-week furazolidone-based quadruple therapy as the first-line treatment for <i>Helicobacter pylori</i> infection in Iran. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 1399-1403.	1.4	16
591	Nitrofurantoin-based regimens for the eradication of <i>Helicobacter pylori</i> infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 1571-1581.	1.4	39
592	Asiaâ€“Pacific consensus on the management of gastroesophageal reflux disease: Update. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 8-22.	1.4	156
593	Consensus on chronic gastritis in China ? Second National Consensus Meeting on Chronic Gastritis (14-16 September 2006 Shanghai, China). <i>Journal of Digestive Diseases</i> , 2007, 8, 107-119.	0.7	38
594	Rabeprazole-based eradication therapy for <i>Helicobacter pylori</i> : a large-scale study in Japan. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 1105-1113.	1.9	51
595	First-line triple therapy with levofloxacin for <i>Helicobacter pylori</i> eradication. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 495-500.	1.9	49
596	Review article: <i>Helicobacter pylori</i> eradication for the prevention of gastric cancer. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 25-35.	1.9	41
597	Empirical rescue therapy after <i>Helicobacter pylori</i> treatment failure: a 10-year single-centre study of 500 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 346-354.	1.9	77
598	Antiadhesive property of microalgal polysaccharide extract on the binding of <i>Helicobacter pylori</i> to gastric mucin. <i>FEMS Immunology and Medical Microbiology</i> , 2007, 50, 231-238.	2.7	31
599	Effect of regular ingestion of <i>Saccharomyces boulardii</i> plus inulin or <i>Lactobacillus acidophilus</i> LB in children colonized by <i>Helicobacter pylori</i> . <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2005, 94, 1747-1751.	0.7	88
600	Low-Grade Non-Hodgkin Lymphomas. <i>Seminars in Radiation Oncology</i> , 2007, 17, 198-205.	1.0	30
601	Comparison of 7-day and 14-day Proton Pump Inhibitor-Containing Triple Therapy for <i>Helicobacter pylori</i> Eradication: Neither Treatment Duration Provides Acceptable Eradication Rate in Korea. <i>Helicobacter</i> , 2007, 12, 31-5.	1.6	69



#	ARTICLE	IF	CITATIONS
602	Levofloxacin- vs. Ranitidine Bismuth Citrate-Containing Therapy After H. Pylori Treatment Failure. <i>Helicobacter</i> , 2007, 12, 68-73.	1.6	23
603	Factors Related to <i>Helicobacter pylori</i> Prevalence in an Adult Population in Brazil. <i>Helicobacter</i> , 2007, 12, 82-8.	1.6	66
604	Proof of an Association between <i>Helicobacter pylori</i> and Idiopathic Thrombocytopenic Purpura in Latin America. <i>Helicobacter</i> , 2007, 12, 265-273.	1.6	38
605	Levofloxacin-Containing Triple Therapy to Eradicate the Persistent <i>H. Pylori</i> after a Failed Conventional Triple Therapy. <i>Helicobacter</i> , 2007, 12, 359-363.	1.6	30
606	Eradication of <i>Helicobacter pylori</i> Does Not Reduce the Incidence of Gastroduodenal Ulcers in Patients on Long-term NSAID Treatment: Double-blind, Randomized, Placebo-controlled Trial. <i>Helicobacter</i> , 2007, 12, 477-485.	1.6	61
607	A Pilot Study Evaluating Sequential Administration of a PPI- Amoxicillin Followed by a PPI- Metronidazole- Tetracycline in Turkey. <i>Helicobacter</i> , 2007, 12, 629-632.	1.6	16
608	Second-Line Treatment for <i>Helicobacter pylori</i> Infection: 10-day Moxifloxacin-Based Triple Therapy versus 2-week Quadruple Therapy. <i>Helicobacter</i> , 2007, 12, 623-628.	1.6	41
609	Efficacy and Safety of Faropenem in Eradication Therapy of <i>Helicobacter pylori</i> . <i>Helicobacter</i> , 2007, 12, 618-622.	1.6	5
610	Evolution of <i>Helicobacter pylori</i> Therapy from a Meta-analytical Perspective. <i>Helicobacter</i> , 2007, 12, 50-58.	1.6	77
611	Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for <i>Helicobacter pylori</i> infection after the standard triple therapy. <i>European Journal of Clinical Pharmacology</i> , 2007, 63, 743-749.	0.8	86
612	One Week of Esomeprazole Triple Therapy vs. 1 Week of Omeprazole Triple Therapy Plus 3 Weeks of Omeprazole for Duodenal Ulcer Healing in <i>Helicobacter pylori</i> -Positive Patients. <i>Digestive Diseases and Sciences</i> , 2007, 52, 1505-1512.	1.1	25
613	<i>Helicobacter Pylori</i> Stool Antigen Assay in Hyperemesis Gravidarum: A Risk Factor for Hyperemesis Gravidarum or Not?. <i>Digestive Diseases and Sciences</i> , 2007, 52, 2840-2843.	1.1	21
614	Primary resistance in <i>Helicobacter pylori</i> isolated in children from Iran. <i>Journal of Infection and Chemotherapy</i> , 2007, 13, 291-295.	0.8	45
615	High eradication rate of <i>H. pylori</i> with moxifloxacin-based treatment: a randomized controlled trial. <i>Wiener Klinische Wochenschrift</i> , 2007, 119, 372-378.	1.0	40
616	Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for <i>Helicobacter pylori</i> in a Japanese population: a randomized, double-blind, placebo-controlled trial. <i>Journal of Gastroenterology</i> , 2007, 42, 690-693.	2.3	60
617	<i>Helicobacter pylori</i> et néoplasies gastriques. <i>Journal Africain D'Hepato-Gastroenterologie</i> , 2007, 1, 1-4.	0.0	1
618	Clarithromycin Resistance, Tumor Necrosis Factor Alpha Gene Polymorphism and Mucosal Inflammation Affect <i>H. pylori</i> Eradication Success. <i>Journal of Gastrointestinal Surgery</i> , 2007, 11, 1506-1514.	0.9	12
619	<i>Helicobacter pylori</i> and benign upper digestive disease. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2007, 21, 261-279.	1.0	25

#	ARTICLE	IF	CITATIONS
620	A historical perspective of <i>Helicobacter gastroduodenitis</i> and its complications. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2007, 21, 335-346.	1.0	14
621	Specific T cell responses to <i>Helicobacter pylori</i> predict successful eradication therapy. <i>Journal of Infection</i> , 2007, 54, 257-261.	1.7	14
622	The Diagnostic Yield of Various Tests for <i>Helicobacter pylori</i> Infection in Patients on Acid-Reducing Drugs. <i>Digestive Diseases and Sciences</i> , 2008, 53, 95-100.	1.1	12
623	Roles of NSAIDs and aspirin in bleeding peptic ulcers. <i>Clinical Journal of Gastroenterology</i> , 2008, 1, 33-39.	0.4	2
624	Role of host interleukin 1 $\beta$ gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in clinical outcomes in <i>Helicobacter pylori</i> -positive Turkish patients with dyspepsia. <i>Journal of Gastroenterology</i> , 2008, 43, 705-710.	2.3	27
625	Cloning, polymorphism, and inhibition of $\beta$ -carbonic anhydrase of <i>Helicobacter pylori</i> . <i>Journal of Gastroenterology</i> , 2008, 43, 849-857.	2.3	48
626	Short-term triple therapy with azithromycin for <i>Helicobacter pylori</i> eradication: Low cost, high compliance, but low efficacy. <i>BMC Gastroenterology</i> , 2008, 8, 20.	0.8	8
627	Probiotics: Benefits in Human Health and Bacterial Disease Management. , 0, , 275-295.		0
628	Epidemiology of acute upper gastrointestinal bleeding. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2008, 22, 209-224.	1.0	314
629	Oneâ€Week Onceâ€Daily Triple Therapy with Esomeprazole, Moxifloxacin, and Rifabutin for Eradication of Persistent <i>Helicobacter pylori</i> Resistant to Both Metronidazole and Clarithromycin. <i>Helicobacter</i> , 2008, 13, 69-74.	1.6	62
630	Evaluation of a Novel Monoclonalâ€Based Antigenâ€inâ€Stool Enzyme Immunoassay (Premier Platinum HpSA) Tj ETQq0 0 0 rgBT /Overl 13, 269-273.	1.6	29
631	The Effects of Probiotics on PPIâ€Triple Therapy for <i>Helicobacter pylori</i> Eradication. <i>Helicobacter</i> , 2008, 13, 261-268.	1.6	108
632	Comparative Study of <i>Helicobacter pylori</i> Eradication Rates of Twiceâ€Versus Fourâ€Timesâ€Daily Amoxicillin Administered with Proton Pump Inhibitor and Clarithromycin: A Randomized Study. <i>Helicobacter</i> , 2008, 13, 282-287.	1.6	15
633	Functional Role of Metaplastic Paneth Cell Defensins in <i>Helicobacter pylori</i> -Infected Stomach. <i>Helicobacter</i> , 2008, 13, 370-379.	1.6	22
634	Clarithromycin Resistance of <i>Helicobacter pylori</i> Strains Isolated from Childrenâ€™ Gastric Antrum and Fundus as Assessed by Fluorescent Inâ€situ Hybridization and Culture on Fourâ€Sector Agar Plates. <i>Helicobacter</i> , 2008, 13, 557-563.	1.6	26
635	Lafutidine versus Lansoprazole in Combination with Clarithromycin and Amoxicillin for One versus Two Weeks for <i>Helicobacter pylori</i> Eradication in Korea. <i>Helicobacter</i> , 2008, 13, 542-549.	1.6	23
636	State and trait anxiety and depression in patients affected by gastrointestinal diseases: psychometric evaluation of 1641 patients referred to an internal medicine outpatient setting. <i>International Journal of Clinical Practice</i> , 2008, 62, 1063-1069.	0.8	120
637	Conjugated linoleic acids produced by <i>Lactobacillus dissociates</i> IKK- $\beta$ and Hsp90 complex in <i>Helicobacter pylori</i> -infected gastric epithelial cells. <i>Laboratory Investigation</i> , 2008, 88, 541-552.	1.7	35

#	ARTICLE	IF	CITATIONS
638	Helicobacter pylori eradication improves gastric histology and decreases serum gastrin, pepsinogen I and pepsinogen II levels in patients with duodenal ulcer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1666-1671.	1.4	41
639	Clarithromycin-based triple therapy as a third-line regimen for <i>Helicobacter pylori</i> eradication. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, S167-70.	1.4	26
640	Normalization of pH level and gastric mucosa after eradication of <i>H. pylori</i> in the remnant stomach. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, S258-61.	1.4	18
641	CYP2C19 genotypes and <i>Helicobacter pylori</i> eradication. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1163-1163.	1.4	8
642	Efficacy of the natural antioxidant astaxanthin in the treatment of functional dyspepsia in patients with or without <i>Helicobacter pylori</i> infection: A prospective, randomized, double blind, and placebo-controlled study. <i>Phytomedicine</i> , 2008, 15, 391-399.	2.3	76
644	<i>Helicobacter pylori</i> infection: A clinical overview. <i>Digestive and Liver Disease</i> , 2008, 40, 619-626.	0.4	105
645	Probiotics—From Metchnikoff to bioactives. <i>International Dairy Journal</i> , 2008, 18, 714-728.	1.5	667
646	Gastrointestinal and Cardiovascular Risks of Nonsteroidal Anti-inflammatory Drugs. <i>American Journal of Medicine</i> , 2008, 121, 464-474.	0.6	81
647	Application of polymerase chain reaction-based assays for rapid identification and antibiotic resistance screening of <i>Helicobacter pylori</i> in gastric biopsies. <i>Diagnostic Microbiology and Infectious Disease</i> , 2008, 61, 67-71.	0.8	24
648	Factors Affecting Physicians' Practices Related to <i>Helicobacter pylori</i> Infection: Effect of Experience and Mode of Practice. <i>Digestion</i> , 2008, 78, 77-81.	1.2	2
649	An Alternative Salvage Regimen for <i>Helicobacter pylori</i> -Resistant Patients with Heart Failure. <i>Cardiology</i> , 2008, 110, 112-115.	0.6	3
650	Preoperative Versus Postoperative <i>Helicobacter pylori</i> Eradication Therapy in Gastric Cancer Patients: A Randomized Trial. <i>American Journal of Gastroenterology</i> , 2008, 103, 48-54.	0.2	11
651	Effective Prevention and Treatment of <i>Helicobacter pylori</i> Infection Using a Combination of Catechins and Sialic Acid in AGS Cells and BALB/c Mice. <i>Journal of Nutrition</i> , 2008, 138, 2084-2090.	1.3	56
652	Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant <i>Helicobacter pylori</i> clinical isolates. <i>Journal of Clinical Pathology</i> , 2008, 61, 1112-1115.	1.0	61
654	Defensin Expression in the Gastric Tissue of Children with <i>Helicobacter pylori</i> -Associated Chronic Gastritis: An Immunohistochemical Study. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2008, 46, 474-477.	0.9	9
655	Role of symptoms in diagnosis and outcome of gastric cancer. <i>World Journal of Gastroenterology</i> , 2008, 14, 1149.	1.4	151
656	Drug utilization of clarithromycin for gastrointestinal disease treatment. <i>World Journal of Gastroenterology</i> , 2008, 14, 6065.	1.4	7
657	Guidelines for Prevention of NSAID-Related Ulcer Complications. <i>American Journal of Gastroenterology</i> , 2009, 104, 728-738.	0.2	17

#	ARTICLE	IF	CITATIONS
658	Clarithromycin and Amoxicillin Susceptibility Testing of <i>Helicobacter pylori</i> by Disk Diffusion Method. Taehan Hmsang Misaengmul Hakhoe Chi = Korean Journal of Clinical Microbiology, 2009, 12, 30.	0.5	1
659	Quinolone-Based Third-Line Therapy for <i>Helicobacter pylori</i> Eradication. Journal of Clinical Biochemistry and Nutrition, 2009, 44, 119-124.	0.6	49
660	Inflammatory Disorders of the Stomach. , 2009, , 269-320.		8
661	Cumulative <i>H. pylori</i> Eradication Rates in Clinical Practice by Adopting First and Second-Line Regimens Proposed by the Maastricht III Consensus and a Third-Line Empirical Regimen. American Journal of Gastroenterology, 2009, 104, 21-25.	0.2	135
662	Comparison of azithromycin and metronidazole in a quadruple-therapy regimen for <i>Helicobacter pylori</i> eradication in dyspepsia. Saudi Journal of Gastroenterology, 2009, 15, 225.	0.5	13
663	Efficacy of levofloxacin-based rescue therapy for <i>Helicobacter pylori</i> infection after standard triple therapy: a randomized controlled trial. Journal of Antimicrobial Chemotherapy, 2009, 63, 1017-1024.	1.3	86
664	A new approach for the prevention and treatment of <i>Helicobacter pylori</i> infection via upregulation of autophagy and downregulation of apoptosis. Autophagy, 2009, 5, 413-414.	4.3	21
666	Exploring the cost-effectiveness of <i>Helicobacter pylori</i> screening to prevent gastric cancer in China in anticipation of clinical trial results. International Journal of Cancer, 2009, 124, 157-166.	2.3	84
667	Second-line treatment for <i>Helicobacter pylori</i> infection based on moxifloxacin triple therapy: a randomized controlled trial. Wiener Klinische Wochenschrift, 2009, 121, 47-52.	1.0	21
668	The Relationship Between Virulence Factors of <i>Helicobacter pylori</i> and Severity of Gastritis in Infected Patients. Digestive Diseases and Sciences, 2009, 54, 103-110.	1.1	35
669	Efficacy of a New Therapeutic Regimen Versus Two Routinely Prescribed Treatments for Eradication of <i>Helicobacter Pylori</i> : A Randomized, Double-Blind Study of Doxycycline, Co-Amoxiclav, and Omeprazole in Iranian Patients. Digestive Diseases and Sciences, 2009, 54, 599-603.	1.1	23
670	Investigations on the amalgamation of gold nanorods by iodine and the detection of tetracycline. Science in China Series B: Chemistry, 2009, 52, 188-195.	0.8	6
671	<i>Helicobacter pylori</i> related dyspepsia: prevalence and treatment outcomes at University Kebangsaan Malaysia-Primary Care Centre. Asia Pacific Family Medicine, 2009, 8, 4.	0.4	5
672	Symptoms in patients on long-term proton pump inhibitors: prevalence and predictors. Alimentary Pharmacology and Therapeutics, 2009, 29, 431-439.	1.9	28
673	What Is the Best Strategy for Diagnosis and Treatment of <i>Helicobacter pylori</i> in the Prevention of Recurrent Peptic Ulcer Bleeding? A Cost-Effectiveness Analysis. Value in Health, 2009, 12, 759-762.	0.1	10
674	Impact of Quadruple Regimen of Clarithromycin Added to Metronidazole-Containing Triple Therapy Against <i>Helicobacter pylori</i> Infection Following Clarithromycin-Containing Triple Therapy Failure. Helicobacter, 2009, 14, 91-99.	1.6	46
675	Meta-Analysis: The Effect of Supplementation with Lactoferrin on Eradication Rates and Adverse Events During <i>Helicobacter pylori</i> Eradication Therapy. Helicobacter, 2009, 14, 119-127.	1.6	21
676	Meta-Analysis: <i>Lactobacillus</i> Containing Quadruple Therapy Versus Standard Triple First-Line Therapy for <i>Helicobacter pylori</i> Eradication. Helicobacter, 2009, 14, 449-459.	1.6	105

#	ARTICLE	IF	CITATIONS
677	Variables Influencing Outcome of <i>Helicobacter pylori</i> Eradication Therapy in South China. <i>Helicobacter</i> , 2009, 14, 443-448.	1.6	23
678	The Modified Sequential Treatment Regimen Containing Levofloxacin for <i>Helicobacter pylori</i> Eradication in Turkey. <i>Helicobacter</i> , 2009, 14, 520-524.	1.6	16
679	Formulation and evaluation of stomach-specific amoxicillin-loaded carbopol-934P mucoadhesive microspheres for anti- <i>Helicobacter pylori</i> therapy. <i>Journal of Microencapsulation</i> , 2009, 26, 365-376.	1.2	30
680	Guidelines for Prevention of NSAID-Related Ulcer Complications. <i>American Journal of Gastroenterology</i> , 2009, 104, 728-738.	0.2	602
681	The efficacy of ranitidine bismuth citrate, amoxicillin and doxycycline or tetracycline regimens as a first line treatment for <i>Helicobacter pylori</i> eradication. <i>European Journal of Internal Medicine</i> , 2009, 20, 53-57.	1.0	20
682	Protective immunization with homologous and heterologous antigens against <i>Helicobacter suis</i> challenge in a mouse model. <i>Vaccine</i> , 2009, 27, 1416-1421.	1.7	6
683	Efficacy of <i>Helicobacter pylori</i> eradication therapy in chronic liver disease. <i>Digestive and Liver Disease</i> , 2009, 41, 134-140.	0.4	19
684	Second-line levofloxacin-based triple schemes for <i>Helicobacter pylori</i> eradication. <i>Digestive and Liver Disease</i> , 2009, 41, 480-485.	0.4	53
685	Illustrating Economic Evaluation of Diagnostic Technologies: Comparing <i>Helicobacter pylori</i> Screening Strategies in Prevention of Gastric Cancer in Canada. <i>Journal of the American College of Radiology</i> , 2009, 6, 317-323.	0.9	25
686	Refractory Peptic Ulcer Disease. <i>Gastroenterology Clinics of North America</i> , 2009, 38, 267-288.	1.0	22
687	Review: Second-line rescue therapy of <i>Helicobacter pylori</i> infection. <i>Therapeutic Advances in Gastroenterology</i> , 2009, 2, 331-356.	1.4	26
688	Platelet response to <i>Helicobacter pylori</i> eradication therapy in adult chronic idiopathic thrombocytopenic purpura seems to be related to the presence of anticytotoxin-associated gene A antibodies. <i>Blood Coagulation and Fibrinolysis</i> , 2009, 20, 108-113.	0.5	20
689	The Impact of Probiotic on Gut Health. <i>Current Drug Metabolism</i> , 2009, 10, 68-78.	0.7	190
690	Moxifloxacin-Based Triple Therapy Versus Clarithromycin-Based Triple Therapy for First-Line Treatment of <i>Helicobacter pylori</i> Infection: A Meta-Analysis of Randomized Controlled Trials. <i>Internal Medicine</i> , 2009, 48, 2069-2076.	0.3	27
691	Clarithromycin Resistance and Efficacy of Clarithromycin-Containing Triple Eradication Therapy for <i>Helicobacter pylori</i> Infection in Type 2 Diabetes Mellitus Patients. <i>Southern Medical Journal</i> , 2009, 102, 1116-1120.	0.3	27
692	Evidence of an inverse relationship between cytotoxin-associated gene A-positive <i>Helicobacter pylori</i> infection and oesophageal adenocarcinoma and possible geographical implications. <i>The Southern African Journal of Epidemiology &amp; Infection: Official Journal of the Sexually Transmitted Diseases, Infectious Diseases and Epidemiological Societies of Southern Africa</i> , 2009, 24, 50-50.	0.2	0
693	Increased Body Mass Index After <i>H. pylori</i> Eradication for Duodenal Ulcer Predisposes to Erosive Reflux Esophagitis. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 705-710.	1.1	12
694	Ten and Eight-day Sequential Therapy in Comparison to Standard Triple Therapy for Eradicating <i>Helicobacter pylori</i> Infection. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 261-266.	1.1	65

#	ARTICLE	IF	CITATIONS
695	A placebo-controlled trial of 10-day bismuth-based quadruple therapy to eradicate <i>Helicobacter pylori</i> infection; a pilot study for the large Linq County trial. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 597-601.	0.8	9
696	Screening of <i>Helicobacter pylori</i> Infection After Gastrectomy for Cancer or Peptic Ulcer. <i>Archives of Surgery</i> , 2010, 145, 962.	2.3	11
698	Is Antimicrobial Susceptibility Testing Necessary Before First-line Treatment for <i>Helicobacter pylori</i> Infection? -Meta-analysis of Randomized Controlled Trials-. <i>Internal Medicine</i> , 2010, 49, 1103-1109.	0.3	88
699	Bismuth-Containing Quadruple Therapy as Second-Line Treatment for <i>Helicobacter pylori</i> Infection: Effect of Treatment Duration and Antibiotic Resistance on the Eradication Rate in Korea. <i>Helicobacter</i> , 2010, 15, 38-45.	1.6	109
700	Guidelines for the Management of <i>Helicobacter pylori</i> Infection in Japan: 2009 Revised Edition. <i>Helicobacter</i> , 2010, 15, 1-20.	1.6	416
701	Role of Probiotics in Pediatric Patients with <i>Helicobacter pylori</i> Infection: A Comprehensive Review of the Literature. <i>Helicobacter</i> , 2010, 15, 79-87.	1.6	70
702	Rabeprazole Can Overcome the Impact of CYP2C19 Polymorphism on Quadruple Therapy. <i>Helicobacter</i> , 2010, 15, 265-272.	1.6	40
703	Structural modification of a specific antimicrobial lead against <i>Helicobacter pylori</i> discovered from traditional Chinese medicine and a structure-activity relationship study. <i>European Journal of Medicinal Chemistry</i> , 2010, 45, 5258-5264.	2.6	37
704	Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent <i>Helicobacter pylori</i> infection: a meta analysis. <i>Wiener Klinische Wochenschrift</i> , 2010, 122, 413-422.	1.0	54
705	Peptide Extracts from Cultures of Certain Lactobacilli Inhibit <i>Helicobacter pylori</i> . <i>Probiotics and Antimicrobial Proteins</i> , 2010, 2, 26-36.	1.9	5
706	Chemometric descriptors in modeling the carbonic anhydrase inhibition activity of sulfonamide and sulfamate derivatives. <i>Molecular Diversity</i> , 2010, 14, 371-384.	2.1	17
707	Cost-effectiveness of six strategies for <i>Helicobacter pylori</i> diagnosis and management in uninvestigated dyspepsia assuming a high resource intensity practice pattern. <i>BMC Health Services Research</i> , 2010, 10, 344.	0.9	18
708	Selected South African Honeys and Their Extracts Possess In Vitro Anti- <i>Helicobacter pylori</i> Activity. <i>Archives of Medical Research</i> , 2010, 41, 324-331.	1.5	44
709	Antimicrobial resistance of <i>H. pylori</i> to the outcome of 10-days vs. 7-days Moxifloxacin based therapy for the eradication: a randomized controlled trial. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2010, 9, 13.	1.7	17
710	Comparison of the once-daily levofloxacin-containing triple therapy with the twice-daily standard triple therapy for first-line <i>Helicobacter pylori</i> eradication: a prospective randomised study. <i>International Journal of Clinical Practice</i> , 2010, 64, 1530-1534.	0.8	15
711	Clinical trial: irsogladine maleate, a mucosal protective drug, accelerates gastric ulcer healing after treatment for eradication of <i>Helicobacter pylori</i> infection - the results of a multicentre, double-blind, randomized clinical trial (IMPACT study). <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 824-833.	1.9	20
712	Comparison of the efficacy of triple versus quadruple therapy on the eradication of <i>Helicobacter pylori</i> and antibiotic resistance. <i>Journal of Digestive Diseases</i> , 2010, 11, 313-318.	0.7	53
713	Marshall and Warren Lecture 2009: Peptic Ulcer Bleeding: An expedition of 20 years from 1989-2009. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 229-233.	1.4	14

#	ARTICLE	IF	CITATIONS
714	Indications to Upper Gastrointestinal Endoscopy in Children With Dyspepsia. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2010, 50, 493-499.	0.9	23
715	Mucosal patterns of <i>Helicobacter pylori</i> -related gastritis without atrophy in the gastric corpus using standard endoscopy. <i>World Journal of Gastroenterology</i> , 2010, 16, 496.	1.4	26
717	Review: Evaluation and management of dyspepsia. <i>Therapeutic Advances in Gastroenterology</i> , 2010, 3, 87-98.	1.4	35
718	CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of <i>Helicobacter pylori</i> infection. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 29-41.	1.5	46
720	A Randomized Controlled Trial: Efficacy and Safety of Azithromycin, Ofloxacin, Bismuth, and Omeprazole Compared With Amoxicillin, Clarithromycin, Bismuth, and Omeprazole as Second-Line Therapy in Patients With <i>Helicobacter pylori</i> Infection. <i>Helicobacter</i> , 2010, 15, 154-159.	1.6	34
721	Antibiotic resistance of <i>Helicobacter pylori</i> in Israeli children. <i>Scandinavian Journal of Gastroenterology</i> , 2010, 45, 550-555.	0.6	26
722	In vitro and in vivo anti- <i>Helicobacter/Campylobacter</i> activity of the aqueous extract of <i>Enantia chlorantha</i> . <i>Pharmaceutical Biology</i> , 2010, 48, 349-356.	1.3	12
723	Probiotic lactobacilli and bifidobacteria in a fermented milk product with added fruit preparation reduce antibiotic associated diarrhea and <i>Helicobacter pylori</i> activity. <i>Journal of Dairy Research</i> , 2011, 78, 396-403.	0.7	70
724	The efficacy of a 1-week triple therapy for eradication of <i>Helicobacter pylori</i> infection in children. <i>Arab Journal of Gastroenterology</i> , 2011, 12, 37-39.	0.4	3
725	Efficacy of Levofloxacin and Rifaximin based Quadruple Therapy in <i>Helicobacter pylori</i> Associated Gastrointestinal Disease: A Double-Blind, Randomized Controlled Trial. <i>Journal of Korean Medical Science</i> , 2011, 26, 785.	1.1	28
727	Scoping a perforated bleeding peptic ulcer: learning points. <i>BMJ Case Reports</i> , 2011, 2011, bcr0820103285-bcr0820103285.	0.2	0
729	Clarithromycin resistance and 23S rRNA mutations in <i>Helicobacter pylori</i> isolates in Iran. <i>African Journal of Microbiology Research</i> , 2011, 5, 853-856.	0.4	17
730	Second-Line Levofloxacin-Based Triple Therapy's Efficiency for <i>Helicobacter pylori</i> Eradication in Patients With Peptic Ulcer. <i>Southern Medical Journal</i> , 2011, 104, 579-583.	0.3	12
731	A randomized trial of standard-dose versus half-dose rabeprazole, clarithromycin, and amoxicillin in the treatment of <i>Helicobacter pylori</i> infection. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 865-870.	0.8	9
732	Triple Therapy with Ecabet Sodium, Amoxicillin and Lansoprazole for 2 Weeks as the Rescue Regimen for <i>H. pylori</i> Infection. <i>Internal Medicine</i> , 2011, 50, 369-374.	0.3	14
733	Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for <i>Helicobacter pylori</i> in Korea. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1098-1105.	1.9	61
734	The effectiveness of systemic eradication therapy against oral <i>Helicobacter pylori</i> . <i>Journal of Oral Pathology and Medicine</i> , 2011, 40, 428-432.	1.4	24
735	Nutrigenomic approach to tackle the unpleasant journey to <i>Helicobacter pylori</i> -associated gastric carcinogenesis. <i>Journal of Digestive Diseases</i> , 2011, 12, 157-164.	0.7	6

#	ARTICLE	IF	CITATIONS
736	Effectiveness and Safety of Repeated Quadruple Therapy in Helicobacter pylori Infection After Failure of Second-line Quadruple Therapy. <i>Helicobacter</i> , 2011, 16, 410-414.	1.6	18
737	First-time Urea Breath Tests Performed at Home by 36,629 Patients: A Study of Helicobacter pylori Prevalence in Primary Care. <i>Helicobacter</i> , 2011, 16, 468-474.	1.6	17
738	Process for detecting Helicobacter pylori using aliphatic amides. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 401, 1889-1898.	1.9	7
739	Healing Effects of Rebamipide and Omeprazole in Helicobacter pylori-Positive Gastric Ulcer Patients after Eradication Therapy: A Randomized Double-Blind, Multinational, Multi-Institutional Comparative Study. <i>Digestion</i> , 2011, 84, 221-229.	1.2	15
740	Comparison of the efficacy of irsogladine maleate and famotidine for the healing of gastric ulcers after Helicobacter pylori eradication therapy: a randomized, controlled, prospective study. <i>Scandinavian Journal of Gastroenterology</i> , 2011, 46, 287-292.	0.6	15
741	Multifaceted Assessment of Chronic Gastritis: A Study of Correlations between Serological, Endoscopic, and Histological Diagnostics. <i>Gastroenterology Research and Practice</i> , 2011, 2011, 1-7.	0.7	16
742	Impact of Lactobacillus reuteri Supplementation on Anti-Helicobacter pylori Levofloxacin-Based Second-Line Therapy. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-6.	0.7	64
743	Rescue Therapy for Helicobacter pylori Infection 2012. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-12.	0.7	34
744	Helicobacter Pylori Infections in Chronic Obstructive Pulmonary Disease. <i>Eurasian Journal of Medicine</i> , 2012, 44, 144-148.	0.2	2
745	Modified Sequential Therapy Regimen versus Conventional Triple Therapy for Helicobacter pylori Eradication in Duodenal Ulcer Patients in China: A Multicenter Clinical Comparative Study. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-8.	0.7	13
746	Helicobacter pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-9.	0.7	32
747	Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). <i>Endoscopy</i> , 2012, 44, 74-94.	1.0	594
749	Test and treat policy in dyspepsia: time for a reappraisal. <i>Tropical Doctor</i> , 2012, 42, 109-111.	0.2	3
750	Pharmacokinetic interactions between ilaprazole and clarithromycin following ilaprazole, clarithromycin and amoxicillin triple therapy. <i>Acta Pharmacologica Sinica</i> , 2012, 33, 1095-1100.	2.8	12
751	Guide Regarding Choice of Second-Line Therapy to Obtain a High Cumulative Cure Rate. <i>Helicobacter</i> , 2012, 17, 243-245.	1.6	11
752	Prevalence of a marker of active helicobacter pylori infection among patients with type 2 diabetes mellitus in Lagos, Nigeria. <i>BMC Research Notes</i> , 2012, 5, 284.	0.6	24
753	Evaluation of Helicobacter Pylori eradication in pediatric patients by triple therapy plus lactoferrin and probiotics compared to triple therapy alone. <i>Italian Journal of Pediatrics</i> , 2012, 38, 63.	1.0	48
754	Preparation and characterization of amoxicillin mucoadhesive microparticles using solution-enhanced dispersion by supercritical CO <sub>2</sub> . <i>Journal of Microencapsulation</i> , 2012, 29, 398-408.	1.2	10



#	ARTICLE	IF	CITATIONS
755	Management of <i>Helicobacter pylori</i> infection—the Maastricht IV/ Florence Consensus Report. <i>Gut</i> , 2012, 61, 646-664.	6.1	2,023
756	Additional corpus biopsy enhances the detection of <i>Helicobacter pylori</i> infection in a background of gastritis with atrophy. <i>BMC Gastroenterology</i> , 2012, 12, 182.	0.8	42
757	Comparison of the Antibiotic Resistance of <i>Helicobacter pylori</i> isolated in Jinju Over a 15-year Period. <i>Journal of Bacteriology and Virology</i> , 2012, 42, 305.	0.0	6
758	Dyspepsia and non-invasive testing for <i>Helicobacter pylori</i> . <i>Gastrointestinal Nursing</i> , 2012, 10, 17-18.	0.0	0
759	Metal organic frameworks for drug delivery and environmental remediation: A molecular docking approach. <i>International Journal of Quantum Chemistry</i> , 2012, 112, 3346-3355.	1.0	47
760	Evaluation of a Four-drug, Three-antibiotic, Nonbismuth-containing Concomitant Therapy as First-line <i>Helicobacter pylori</i> Eradication Regimen in Greece. <i>Helicobacter</i> , 2012, 17, 49-53.	1.6	38
761	Randomised clinical trial: comparative study of 10-day sequential therapy with 7-day standard triple therapy for <i>Helicobacter pylori</i> infection in naïve patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 56-65.	1.9	73
762	Pathology of oesophagitis. <i>Histopathology</i> , 2012, 60, 864-879.	1.6	19
763	“Is it effective?” to “How to use it?”—the era has changed in probiotics and functional food products against <i>Helicobacter pylori</i> infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 851-853.	1.4	5
764	Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012, 460, 12-16.	1.4	111
765	Narrow band imaging versus white light gastroscopy in detecting potentially premalignant gastric lesions: a randomized prospective crossover study. <i>Indian Journal of Gastroenterology</i> , 2013, 32, 37-42.	0.7	30
766	Multi-center randomized controlled study to establish the standard third-line regimen for <i>Helicobacter pylori</i> eradication in Japan. <i>Journal of Gastroenterology</i> , 2013, 48, 1128-1135.	2.3	75
767	The role of small intestinal bacterial overgrowth in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 1241-1249.	2.2	267
768	Cumulative <i>Helicobacter pylori</i> Eradication Therapy in Obese Patients Undergoing Gastric Bypass Surgery. <i>Obesity Surgery</i> , 2013, 23, 145-149.	1.1	14
769	Efficacy of Two Levofloxacin-Containing Second-Line Therapies for <i>Helicobacter pylori</i> : A Pilot Study. <i>Helicobacter</i> , 2013, 18, 378-383.	1.6	16
770	Mitigating GI Risks Associated with the Use of NSAIDs: Table 1. <i>Pain Medicine</i> , 2013, 14, S18-S22.	0.9	5
771	Prevalence and risk factors of <i>Helicobacter pylori</i> in Turkey: a nationally-representative, cross-sectional, screening with the 13C-Urea breath test. <i>BMC Public Health</i> , 2013, 13, 1215.	1.2	117
772	The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage. <i>Arthritis Research and Therapy</i> , 2013, 15, S5.	1.6	77

#	ARTICLE	IF	CITATIONS
773	Prevalence of <i>Helicobacter pylori</i> infection in bariatric patients: a histologic assessment. <i>Surgery for Obesity and Related Diseases</i> , 2013, 9, 679-685.	1.0	27
774	Diagnostic testing for <i>Helicobacter Pylori</i> in patients with atrophic gastritis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2013, 37, e115-e116.	0.7	1
775	Current options for the treatment of <i>Helicobacter pylori</i> . <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 211-223.	0.9	50
776	The ferric uptake regulator of <i>Helicobacter pylori</i> : a critical player in the battle for iron and colonization of the stomach. <i>Future Microbiology</i> , 2013, 8, 725-738.	1.0	44
777	<i>Helicobacter pylori</i> Infection and Upper Gastrointestinal Disorders. <i>Gastroenterology Research and Practice</i> , 2013, 2013, 1-3.	0.7	3
778	<i>Helicobacter pylori</i> eradication therapy: A review of current trends. <i>Nigerian Medical Journal</i> , 2013, 54, 1.	0.6	21
779	Changing pattern of antibiotic resistance of <i>Helicobacter pylori</i> in children during 20 years in Jinju, South Korea. <i>Pediatrics International</i> , 2013, 55, 332-336.	0.2	34
780	Randomised clinical trial: the effects of <i>Helicobacter pylori</i> eradication on glandular atrophy and intestinal metaplasia after subtotal gastrectomy for gastric cancer. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 477-489.	1.9	35
781	Optimum duration of regimens for <i>Helicobacter pylori</i> eradication. <i>The Cochrane Library</i> , 2013, , CD008337.	1.5	120
782	Nonbismuth Quadruple Concomitant Therapy Versus Standard Triple Therapy, Both of the Duration of 10 Days, for First-Line H. Pylori Eradication. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 228-232.	1.1	45
783	Standard triple versus levofloxacin based regimen for eradication of <i>Helicobacter pylori</i> . <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2013, 4, 23.	0.6	9
784	Increasing gastric juice pH level prior to anti- <i>Helicobacter pylori</i> therapy may be beneficial to the healing of duodenal ulcers. <i>Experimental and Therapeutic Medicine</i> , 2013, 5, 912-916.	0.8	12
785	The Relationship between Bioactive Compounds with Diastase Activity and Antibacterial Synergy of Honey and Potato Starch Combinations against <i>Klebsiella pneumoniae</i> . <i>Clinical Microbiology (Los Angeles)</i> , 2013, 10, 50-52.	0.0	0
786	<i>Helicobacter pylori</i> Current Therapy and Future Therapeutic Strategies. , 0, , .		1
787	A review of <i>Helicobacter pylori</i> diagnosis, treatment, and methods to detect eradication. <i>World Journal of Gastroenterology</i> , 2014, 20, 1438.	1.4	165
788	Meta-analysis of the efficacy of probiotics in <i>Helicobacter pylori</i> eradication therapy. <i>World Journal of Gastroenterology</i> , 2014, 20, 18013-18021.	1.4	85
789	Anti- <i>Helicobacter pylori</i> activity of antimicrobial substances produced by lactic acid bacteria isolated from Baikkimchi. <i>Journal of the Korean Society for Applied Biological Chemistry</i> , 2014, 57, 621-630.	0.9	14
790	Bacteria: <i>Helicobacter pylori</i> . , 2014, , 446-449.		1

#	ARTICLE	IF	CITATIONS
791	Diagnosis, Treatment, and Outcome in Patients with Bleeding Peptic Ulcers and <i>Helicobacter pylori</i> Infections. <i>BioMed Research International</i> , 2014, 2014, 1-10.	0.9	19
792	Therapy of <i>Helicobacter pylori</i> : Present Medley and Future Prospective. <i>BioMed Research International</i> , 2014, 2014, 1-7.	0.9	35
793	Eradication of <i>Helicobacter pylori</i> infection: Which regimen first?. <i>World Journal of Gastroenterology</i> , 2014, 20, 665.	1.4	36
794	Challenging the dogma: a randomized trial of standard vs. half-dose concomitant nonbismuth quadruple therapy for <i>Helicobacter pylori</i> infection. <i>United European Gastroenterology Journal</i> , 2014, 2, 179-188.	1.6	7
795	Factors Affecting First-Line Triple Therapy of <i>Helicobacter pylori</i> Including CYP2C19 Genotype and Antibiotic Resistance. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1235-1243.	1.1	92
796	Clinical application of probiotics in the treatment of <i>Helicobacter pylori</i> infection—A brief review. <i>Journal of Microbiology, Immunology and Infection</i> , 2014, 47, 429-437.	1.5	81
797	Comparison of <i>Helicobacter pylori</i> eradication rates of standard 14-day quadruple treatment and novel modified 10-day, 12-day and 14-day sequential treatments. <i>European Journal of Internal Medicine</i> , 2014, 25, 224-229.	1.0	8
798	Prediction of <i>Helicobacter pylori</i> Status by Conventional Endoscopy, Narrow-Band Imaging Magnifying Endoscopy in Stomach after Endoscopic Resection of Gastric Cancer. <i>Helicobacter</i> , 2014, 19, 111-115.	1.6	24
799	<i>Saccharomyces boulardii</i> expresses neuraminidase activity selective for $\alpha$ 2,3-linked sialic acid that decreases <i>Helicobacter pylori</i> adhesion to host cells. <i>Apmis</i> , 2014, 122, 941-950.	0.9	59
800	Probiotics: A Comprehensive Approach toward Health Foods. <i>Critical Reviews in Food Science and Nutrition</i> , 2014, 54, 537-552.	5.4	57
801	POTENTIAL IN VITRO ANTI-HELICOBACTER ACTIVITY OF BACTERIOCIN AND BACTERIOCIN-LIKE COMPOUNDS PRODUCED BY LACTOBACILLI. <i>Journal of Microbiology, Biotechnology and Food Sciences</i> , 2014, 04, 160-163.	0.4	0
802	Hematologic manifestations of <i>Helicobacter pylori</i> infection. <i>World Journal of Gastroenterology</i> , 2014, 20, 12818.	1.4	62
803	Treatment of <i>Helicobacter pylori</i> infection: Past, present and future. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2014, 5, 392.	0.5	67
804	Empirical Versus Targeted Treatment of <i>Helicobacter pylori</i> Infections in Southern Poland According to the Results of Local Antimicrobial Resistance Monitoring. , 0, , .		0
805	Fluoroquinolone Sequential Therapy for <i>Helicobacter pylori</i> : A Meta-analysis. <i>Pharmacotherapy</i> , 2015, 35, 719-730.	1.2	12
806	Systematic review and meta-analysis: full- vs. half-dose anti-microbials in clarithromycin-based regimens for <i>Helicobacter pylori</i> eradication. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 131-141.	1.9	12
807	Improved gastric lesion of ulcerogenic mice treated with bark extracts and fractions of <i>Newbouldia laevis</i> . <i>African Journal of Pharmacy and Pharmacology</i> , 2015, 9, 553-560.	0.2	1
808	Expression of interleukin 1 $\beta$ in gastric cancer tissue and its effects on gastric cancer. <i>OncoTargets and Therapy</i> , 2015, 9, 31.	1.0	11

#	ARTICLE	IF	CITATIONS
809	The Diagnostic Validity of Citric Acid-Free, High Dose <sup>13</sup> C-Urea Breath Test After <i>Helicobacter pylori</i> Eradication in Korea. <i>Helicobacter</i> , 2015, 20, 159-168.	1.6	30
810	Hereditary Diffuse Gastric Cancer Syndrome. <i>JAMA Oncology</i> , 2015, 1, 23.	3.4	540
811	Comparative effectiveness and tolerance of treatments for <i>Helicobacter pylori</i> : systematic review and network meta-analysis. <i>BMJ</i> , The, 2015, 351, h4052.	3.0	137
812	Occurrence of <i>Helicobacter pylori</i> in saliva from preschool-age children. <i>Oral Science International</i> , 2015, 12, 5-8.	0.3	0
813	CONVENTIONAL VIDEOENDOSCOPY CAN IDENTIFY HELICOBACTER PYLORI GASTRITIS?. <i>Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery</i> , 2016, 29, 73-76.	0.5	6
814	Diagnostic Methods of <i>Helicobacter pylori</i> Infection for Epidemiological Studies: Critical Importance of Indirect Test Validation. <i>BioMed Research International</i> , 2016, 2016, 1-14.	0.9	96
815	Efficacy of Probiotic Supplementation Therapy for <i>Helicobacter pylori</i> Eradication: A Meta-Analysis of Randomized Controlled Trials. <i>PLoS ONE</i> , 2016, 11, e0163743.	1.1	114
816	Bacteriocins and Its Use for Multidrug-Resistant Bacteria Control. , 2016, , 329-349.		17
817	NSAID-induced Gastrointestinal Injury. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 5-10.	1.1	100
818	<i>Helicobacter pylori</i> infection and gastroesophageal reflux in children. <i>Ecological Management and Restoration</i> , 2016, 29, 1007-1012.	0.2	15
819	Eradication therapy for peptic ulcer disease in <i>Helicobacter pylori</i> -positive people. <i>The Cochrane Library</i> , 2016, 2016, CD003840.	1.5	112
820	IV Spanish Consensus Conference on <i>Helicobacter pylori</i> infection treatment. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2016, 39, 697-721.	0.0	27
821	<i>Helicobacter pylori</i> : past, current and future treatment strategies with gastroretentive drug delivery systems. <i>Journal of Drug Targeting</i> , 2016, 24, 897-915.	2.1	22
822	Pharmacologic Therapies in Gastrointestinal Diseases. <i>Medical Clinics of North America</i> , 2016, 100, 827-850.	1.1	22
823	The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy. <i>American Journal of Gastroenterology</i> , 2016, 111, 949-956.	0.2	88
824	IV Conferencia Española de Consenso sobre el tratamiento de la infección por <i>Helicobacter pylori</i> . <i>Gastroenterología Y Hepatología</i> , 2016, 39, 697-721.	0.2	97
825	Review article: the global emergence of <i>Helicobacter pylori</i> antibiotic resistance. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 514-533.	1.9	546
826	Sequential versus standard triple first-line therapy for <i>Helicobacter pylori</i> eradication. <i>The Cochrane Library</i> , 2016, , CD009034.	1.5	35

#	ARTICLE	IF	CITATIONS
827	A 2-week Nitazoxanide-based quadruple treatment as a rescue therapy for <i>Helicobacter pylori</i> eradication. <i>Medicine (United States)</i> , 2016, 95, e3879.	0.4	29
828	Non-Hodgkin's Lymphoma. , 2016, , 1524-1546.e7.		2
829	<i>Helicobacter pylori</i> treatment: Still a work in progress. <i>Postgraduate Medicine</i> , 2016, 128, 152-157.	0.9	4
830	Floating modular drug delivery systems with buoyancy independent of release mechanisms to sustain amoxicillin and clarithromycin intra-gastric concentrations. <i>Drug Development and Industrial Pharmacy</i> , 2016, 42, 332-339.	0.9	23
831	<i>Lactobacillus paracasei</i> strain O6TCa19 suppresses inflammatory chemokine induced by <i>Helicobacter pylori</i> in human gastric epithelial cells. <i>Human Cell</i> , 2017, 30, 258-266.	1.2	19
832	Validity of Salivary Polymerase Chain Reaction in Diagnosis of <i>Helicobacter pylori</i> Among Egyptian Patients. <i>Infectious Diseases in Clinical Practice</i> , 2017, 25, 76-81.	0.1	1
833	A Serological Biopsy Using Five Stomach-Specific Circulating Biomarkers for Gastric Cancer Risk Assessment: A Multi-Phase Study. <i>American Journal of Gastroenterology</i> , 2017, 112, 704-715.	0.2	81
834	Strategies used by <i>Helicobacter pylori</i> to establish persistent infection. <i>World Journal of Gastroenterology</i> , 2017, 23, 2870.	1.4	83
835	Efficacy and safety of sequential versus quadruple therapy as second-line treatment for <i>Helicobacter pylori</i> infection—A randomized controlled trial. <i>PLoS ONE</i> , 2017, 12, e0183302.	1.1	13
837	Efficacy of Levofloxacin-Based Third-Line Therapy for the Eradication of <i>Helicobacter pylori</i> in Peptic Ulcer Disease. <i>Gut and Liver</i> , 2017, 11, 226-231.	1.4	18
838	Secretion expression of human neutrophil peptide 1 (HNP1) in <i>Pichia pastoris</i> and its functional analysis against antibiotic-resistant <i>Helicobacter pylori</i> . <i>Applied Microbiology and Biotechnology</i> , 2018, 102, 4817-4827.	1.7	16
839	<i>Helicobacter pylori</i> treatment: antibiotics or probiotics. <i>Applied Microbiology and Biotechnology</i> , 2018, 102, 1-7.	1.7	219
840	Treatment of <i>Helicobacter pylori</i> infection: A clinical practice update. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12857.	1.7	56
841	The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy. <i>Journal of the Nihon University Medical Association</i> , 2018, 77, 333-334.	0.0	0
843	The efficacy of first-line regimens for <i>Helicobacter pylori</i> eradication in different continents. <i>Medicine (United States)</i> , 2018, 97, e13682.	0.4	3
844	Antibiotic Resistance Is the Key Element in Treatment of <i>Helicobacter pylori</i> Infection. <i>Gastroenterology</i> , 2018, 155, 1300-1302.	0.6	18
845	Real-time PCR for <i>Helicobacter pylori</i> diagnosis. The best tools available. <i>Helicobacter</i> , 2018, 23, e12512.	1.6	36
846	Ten-day high-dose proton pump inhibitor triple therapy versus sequential therapy for <i>Helicobacter pylori</i> eradication. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1822-1828.	1.4	11

#	ARTICLE	IF	CITATIONS
847	Protocol of the European Registry on the management of <i>Helicobacter pylori</i> infection (Hp-EuReg). <i>Helicobacter</i> , 2019, 24, e12630.	1.6	46
848	Primary antimicrobial resistance rates and prevalence of <i>Helicobacter pylori</i> infection in the north of Spain. A 13-year retrospective study. <i>GastroenterologĀ Y HepatologĀ (English Edition)</i> , 2019, 42, 476-485.	0.0	0
849	Influence of serum vitamin D level on <i>Helicobacter pylori</i> eradication: A multi-center, observational, prospective and cohort study. <i>Journal of Digestive Diseases</i> , 2019, 20, 421-426.	0.7	24
850	Spanish primary care survey on the management of <i>Helicobacter pylori</i> infection and dyspepsia: Information, attitudes, and decisions. <i>Helicobacter</i> , 2019, 24, e12593.	1.6	18
851	Vonoprazan and <i>Helicobacter pylori</i> Treatment: A Lesson From Japan or a Limited Geographic Phenomenon?. <i>Frontiers in Pharmacology</i> , 2019, 10, 316.	1.6	23
852	Herbal medicine as an auspicious therapeutic approach for the eradication of <i>Helicobacter pylori</i> infection: A concise review. <i>Journal of Cellular Physiology</i> , 2019, 234, 16847-16860.	2.0	18
853	Meta-analysis of three single capsule bismuth-containing quadruple therapy for the eradication of <i>Helicobacter pylori</i> . <i>Helicobacter</i> , 2019, 24, e12570.	1.6	57
854	Half-dose clarithromycin-containing bismuth quadruple therapy is effective and economical in treating <i>Helicobacter pylori</i> infection: A single-center, open-label, randomized trial. <i>Helicobacter</i> , 2019, 24, e12566.	1.6	12
855	Probiotic <i>L. gasseri</i> strain (LG21) for the upper gastrointestinal tract acting through improvement of indigenous microbiota. <i>BMJ Open Gastroenterology</i> , 2019, 6, e000314.	1.1	13
856	Self-reported adverse drug effects and associated factors among <i>H. pylori</i> infected patients on standard triple therapy: Prospective follow up study. <i>PLoS ONE</i> , 2019, 14, e0225585.	1.1	4
857	Attenuated Total Reflectance Fourier Transform Infrared Spectroscopy (FTIR) and Artificial Neural Networks Applied to Investigate Quantitative Changes of Selected Soluble Biomarkers, Correlated with <i>H. pylori</i> Infection in Children and Presumable Consequent Delayed Growth. <i>Journal of Clinical Medicine</i> , 2020, 9, 3852.	1.0	16
858	The effect of antibiotic resistance on <i>Helicobacter pylori</i> eradication efficacy: A systematic review and meta-analysis. <i>Helicobacter</i> , 2020, 25, e12714.	1.6	61
859	Association of tobacco smoke-infused water (tuibur) use by Mizo people and risk of <i>Helicobacter pylori</i> infection. <i>Environmental Science and Pollution Research</i> , 2020, 27, 8580-8585.	2.7	5
860	Development of a Method for Assessing <i>Helicobacter pylori</i> Activity Based on Exhaled Air Composition with the Use of an Array of Piezoelectric Chemical Sensors. <i>Journal of Analytical Chemistry</i> , 2020, 75, 553-562.	0.4	6
861	European Registry on <i>Helicobacter pylori</i> management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21%533 patients. <i>Gut</i> , 2021, 70, 40-54.	6.1	139
862	Treatment Approach of Refractory <i>Helicobacter pylori</i> Infection: A Comprehensive Review. <i>Journal of Primary Care and Community Health</i> , 2021, 12, 215013272110140.	1.0	11
863	40 Years of <i>Helicobacter pylori</i> : A Revolution in Biomedical Thought. <i>Gastroenterology Insights</i> , 2021, 12, 111-135.	0.7	45
864	Response of <i>Helicobacter Pylori</i> Eradication Treatment in Patients With Normal and Below-Normal Serum Vitamin D Levels. <i>Cureus</i> , 2021, 13, e14777.	0.2	2

#	ARTICLE	IF	CITATIONS
865	Epidemiological aspects of <i>Helicobacter pylori</i> infection in children. <i>Aktualizacija Infektologija</i> , 2021, 9, 28-32.	0.1	0
866	Primary antibiotic resistance of <i>Helicobacter pylori</i> isolates is twofold more frequent in HIV-positive than HIV-negative individuals: A descriptive observational study. <i>MicrobiologyOpen</i> , 2021, 10, e1184.	1.2	3
867	<i>Helicobacter Pylori</i> Eradication Therapy: Still a Challenge. <i>Cureus</i> , 2021, 13, e14872.	0.2	10
868	Efeitos da melatonina como tratamento complementar de úlceras gastroduodenais: Uma revisão integrativa. <i>Research, Society and Development</i> , 2021, 10, e52310616087.	0.0	0
869	<i>Lactobacillus plantarum</i> ZJ316 Attenuates <i>Helicobacter pylori</i> -Induced Gastritis in C57BL/6 Mice. <i>Journal of Agricultural and Food Chemistry</i> , 2021, 69, 6510-6523.	2.4	28
870	Dyspepsia Challenge in Primary Care Gastroenterology. <i>Digestive Diseases</i> , 2022, 40, 270-275.	0.8	2
871	The Effect of <i>Helicobacter pylori</i> Eradication on Gastric Wall Thickness in Patients Undergoing Laparoscopic Sleeve Gastrectomy. <i>Obesity Surgery</i> , 2021, 31, 4024-4032.	1.1	7
872	In Vitro Screening Potential Antibacterial Properties of the Greek Oregano Honey against Clinical Isolates of <i>Helicobacter pylori</i> . <i>Foods</i> , 2021, 10, 1568.	1.9	3
873	Research Trends on Clinical <i>Helicobacter pylori</i> Eradication: A Bibliometric Analysis from 1983 to 2020. <i>Helicobacter</i> , 2021, 26, e12835.	1.6	8
874	Improving the ability of antimicrobial susceptibility tests to predict clinical outcome accurately: Adding metabolic evasion to the equation. <i>Drug Discovery Today</i> , 2021, 26, 2182-2189.	3.2	4
875	Efficacy of Lactoferrin with Standard Triple Therapy or Sequential Therapy for <i>Helicobacter pylori</i> Eradication: A Randomized Controlled Trial. , 2021, 32, 742-749.		8
879	<i>Helicobacter pylori</i> and dyspepsia strategies – debate: Yes – a test-and-treat strategy is a viable option in primary care. , 2003, , 283-295.		1
880	<i>Magen.</i> , 2007, , 33-55.		1
881	Twice daily (mid-day and evening) quadruple therapy for <i>H. pylori</i> infection in the United States. <i>Digestive and Liver Disease</i> , 2004, 36, 384-387.	0.4	23
882	Quadruple therapy as a first-line <i>Helicobacter pylori</i> treatment: past or future?. <i>Digestive and Liver Disease</i> , 2004, 36, 377-379.	0.4	4
883	Primary antimicrobial resistance rates and prevalence of <i>Helicobacter pylori</i> infection in the north of Spain. A 13-year retrospective study. <i>Gastroenterología Y Hepatología</i> , 2019, 42, 476-485.	0.2	19
884	<i>Infectious Agents.</i> , 2006, , 507-548.		8
885	<i>Stomach Cancer.</i> , 2006, , 707-720.		43

#	ARTICLE	IF	CITATIONS
886	Trends in <i>Helicobacter pylori</i> resistance to clarithromycin: from phenotypic to genomic approaches. <i>Microbial Genomics</i> , 2020, 6, .	1.0	27
887	Comparative Evaluation of 29 Commercial <i>Helicobacter pylori</i> Serological Kits. <i>Helicobacter</i> , 2013, 18, 169-179.	1.6	97
888	Diagnostic Accuracy of Age and Alarm Symptoms for Upper GI Malignancy in Patients with Dyspepsia in a GI Clinic: A 7-Year Cross-Sectional Study. <i>PLoS ONE</i> , 2012, 7, e39173.	1.1	28
889	Second-line treatment for <i>Helicobacter pylori</i> eradication after sequential therapy failure: a pilot study. <i>Therapy: Open Access in Clinical Medicine</i> , 2006, 3, 251-254.	0.2	2
890	Efficacy and tolerability of fourteen-day sequential quadruple regimen: pantoprazole, bismuth, amoxicillin, metronidazole and or furazolidone as first-line therapy for eradication of : a randomized, double-blind clinical trial. <i>EXCLI Journal</i> , 2019, 18, 644-652.	0.5	14
891	Effectiveness and safety of levosulpiride in the treatment of dysmotility-like functional dyspepsia. <i>Therapeutics and Clinical Risk Management</i> , 2007, 3, 149-155.	0.9	33
892	Role of Probiotics in Prophylaxis of <i>Helicobacter pylori</i> Infection. <i>Current Pharmaceutical Biotechnology</i> , 2019, 20, 137-145.	0.9	11
893	Whos Winning the War? Molecular Mechanisms of Antibiotic Resistance in <i>Helicobacter pylori</i> . <i>Current Drug Therapy</i> , 2008, 3, 190-203.	0.2	31
894	Double strain probiotic effect on infection treatment: A double-blinded randomized controlled trial. <i>Caspian Journal of Internal Medicine</i> , 2017, 8, 165-171.	0.1	5
896	Perforated Duodenal Ulcer in a Young Child: An Uncommon Condition. <i>Journal of the Nepal Medical Association</i> , 2013, 48, 165-7.	0.1	6
897	Gastric juice for the diagnosis of <i>H pylori</i> infection in patients on proton pump inhibitors. <i>World Journal of Gastroenterology</i> , 2008, 14, 1539.	1.4	9
898	Is a 7-day <i>Helicobacter pylori</i> treatment enough for eradication and inactivation of gastric inflammatory activity?. <i>World Journal of Gastroenterology</i> , 2008, 14, 2838.	1.4	5
899	Treatment of <i>Helicobacter pylori</i> in surgical practice: A randomised trial of triple versus quadruple therapy in a rural district general hospital. <i>World Journal of Gastroenterology</i> , 2008, 14, 3855.	1.4	23
900	“Rescue” regimens after <i>Helicobacter pylori</i> treatment failure. <i>World Journal of Gastroenterology</i> , 2008, 14, 5385.	1.4	98
901	Short-term Celecoxib intervention is a safe and effective chemopreventive for gastric carcinogenesis based on a Mongolian gerbil model. <i>World Journal of Gastroenterology</i> , 2009, 15, 4907.	1.4	10
902	Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating <i>Helicobacter pylori</i> . <i>World Journal of Gastroenterology</i> , 2004, 10, 1656.	1.4	50
903	Possibility of non-invasive diagnosis of gastric mucosal precancerous changes. <i>World Journal of Gastroenterology</i> , 2004, 10, 3146.	1.4	19
904	Increased activity of Pgp multidrug transporter in patients with <i>Helicobacter pylori</i> infection. <i>World Journal of Gastroenterology</i> , 2005, 11, 2720.	1.4	9



#	ARTICLE	IF	CITATIONS
905	Do patients with non-ulcer dyspepsia respond differently to <i>Helicobacter pylori</i> eradication treatments from those with peptic ulcer disease? A systematic review. <i>World Journal of Gastroenterology</i> , 2005, 11, 2726.	1.4	20
906	Role of <i>Helicobacter pylori</i> eradication in aspirin or non-steroidal anti-inflammatory drug users. <i>World Journal of Gastroenterology</i> , 2005, 11, 3811.	1.4	25
907	Breath and string test: A diagnostic package for the identification of treatment failure and antibiotic resistance of <i>Helicobacter pylori</i> without the necessity of upper gastrointestinal endoscopy. <i>World Journal of Gastroenterology</i> , 2005, 11, 584.	1.4	15
908	Validation of four <i>Helicobacter pylori</i> rapid blood tests in a multi-ethnic Asian population. <i>World Journal of Gastroenterology</i> , 2005, 11, 6681.	1.4	6
909	Stool antigen tests in the diagnosis of <i>Helicobacter pylori</i> infection before and after eradication therapy. <i>World Journal of Gastroenterology</i> , 2005, 11, 7340.	1.4	39
910	<i>Helicobacter pylori</i> infection in hemodialysis patients: Susceptibility to amoxicillin and clarithromycin. <i>World Journal of Gastroenterology</i> , 2005, 11, 842.	1.4	30
911	Response of blood endothelin-1 and nitric oxide activity in duodenal ulcer patients undergoing <i>Helicobacter pylori</i> eradication. <i>World Journal of Gastroenterology</i> , 2005, 11, 1048.	1.4	4
912	Third-line rescue therapy for <i>Helicobacter pylori</i> infection. <i>World Journal of Gastroenterology</i> , 2006, 12, 2313.	1.4	39
913	Remission of primary low-grade gastric lymphomas of the mucosa-associated lymphoid tissue type in immunocompromised pediatric patients. <i>World Journal of Gastroenterology</i> , 2006, 12, 2625.	1.4	14
914	Role of <i>Helicobacter pylori</i> in functional dyspepsia. <i>World Journal of Gastroenterology</i> , 2006, 12, 2677.	1.4	15
915	Comparison of invasive methods and two different stool antigen tests for diagnosis of <i>H pylori</i> infection in patients with gastric bleeding. <i>World Journal of Gastroenterology</i> , 2006, 12, 4206.	1.4	19
916	Azithromycin in one week quadruple therapy for <i>H pylori</i> eradication in Iran. <i>World Journal of Gastroenterology</i> , 2006, 12, 4553.	1.4	10
917	First-line eradication of <i>H pylori</i> infection in Europe: A meta-analysis based on congress abstracts, 1997-2004. <i>World Journal of Gastroenterology</i> , 2006, 12, 5311.	1.4	16
918	Detection of <i>H pylori</i> infection by ELISA and Western blot techniques and evaluation of anti CagA seropositivity in adult Turkish dyspeptic patients. <i>World Journal of Gastroenterology</i> , 2006, 12, 5375.	1.4	17
919	Optimal length of triple therapy for <i>H pylori</i> eradication in a population with high prevalence of infection in Chile. <i>World Journal of Gastroenterology</i> , 2007, 13, 2967.	1.4	7
920	Improvement in symptoms after H <sub>2</sub> -receptor antagonist-based therapy for eradication of <i>H pylori</i> infection. <i>World Journal of Gastroenterology</i> , 2007, 13, 3836.	1.4	8
921	Diagnostic accuracy of a rapid fecal test to confirm <i>H pylori</i> eradication after therapy: Prospective comparison with a laboratory stool test. <i>World Journal of Gastroenterology</i> , 2007, 13, 4484.	1.4	6
922	Omeprazole-based triple therapy with low-versus high-dose of clarithromycin plus amoxicillin for <i>H pylori</i> eradication in Iranian population. <i>World Journal of Gastroenterology</i> , 2007, 13, 930.	1.4	9

#	ARTICLE	IF	CITATIONS
923	Age-dependent eradication of <i>Helicobacter pylori</i> in Japanese patients. World Journal of Gastroenterology, 2010, 16, 4176.	1.4	20
924	Standard triple, bismuth pectin quadruple and sequential therapies for <i>Helicobacter pylori</i> eradication. World Journal of Gastroenterology, 2010, 16, 4357.	1.4	61
925	Five methods for detection of <i>Helicobacter pylori</i> in the Turkish population. World Journal of Gastroenterology, 2011, 17, 5172.	1.4	21
926	Influence of proton pump inhibitor treatment on <i>Helicobacter pylori</i> stool antigen test. World Journal of Gastroenterology, 2012, 18, 44.	1.4	39
927	Levofloxacin/amoxicillin-based schemes vs quadruple therapy for <i>Helicobacter pylori</i> eradication in second-line. World Journal of Gastroenterology, 2012, 18, 5669.	1.4	53
928	Culture-guided treatment approach for <i>Helicobacter pylori</i> infection: Review of the literature. World Journal of Gastroenterology, 2014, 20, 5205.	1.4	38
929	Treatment of <i>Helicobacter pylori</i> infection: Meeting the challenge of antimicrobial resistance. World Journal of Gastroenterology, 2014, 20, 9898.	1.4	95
930	Seven-day quintuple regimen as a rescue therapy for <i>Helicobacter pylori</i> eradication. World Journal of Gastroenterology, 2015, 21, 661.	1.4	15
931	Fourteen- vs seven-day bismuth-based quadruple therapy for second-line <i>Helicobacter pylori</i> eradication. World Journal of Gastroenterology, 2015, 21, 8132.	1.4	12
932	Current evidence of effects of <i>Helicobacter pylori</i> eradication on prevention of gastric cancer. Korean Journal of Internal Medicine, 2013, 28, 525.	0.7	19
933	A clinician's guide to managing <i>Helicobacter pylori</i> infection.. Cleveland Clinic Journal of Medicine, 2005, 72, 109-110.	0.6	13
934	Comparison of one week and two weeks of triple therapy for the eradication of <i>Helicobacter pylori</i> in a Sri Lankan population: a randomised, controlled study. Ceylon Medical Journal, 2010, 49, 118.	0.1	4
935	<i>Helicobacter pylori</i> eradication therapy in nonulcer dyspepsia is beneficial. Saudi Journal of Gastroenterology, 2008, 14, 96.	0.5	4
936	N-acetyl cysteine as an adjunct to standard anti- <i>Helicobacter pylori</i> eradication regimen in patients with dyspepsia: A prospective randomized, open-label trial. Advanced Biomedical Research, 2014, 3, 189.	0.2	6
937	A study of the changes in the cause of peptic ulcer bleeding. World Journal of Gastrointestinal Endoscopy, 2012, 4, 323.	0.4	7
938	Primary clarithromycin resistance to <i>Helicobacter pylori</i> : Is this the main reason for triple therapy failure?. World Journal of Gastrointestinal Pathophysiology, 2013, 4, 43.	0.5	34
939	Indications, diagnostic tests and <i>Helicobacter pylori</i> eradication therapy: Recommendations by the 2nd Spanish Consensus Conference. Revista Espanola De Enfermedades Digestivas, 2005, 97, 348-74.	0.1	30
940	<i>Helicobacter pylori</i> : its discovery and relevance for medicine. Revista Espanola De Enfermedades Digestivas, 2006, 98, 770-85.	0.1	28

#	ARTICLE	IF	CITATIONS
942	Effect of Helicobacter pylori Eradication on the Development of Refl ux Esophagitis and Gastroesophageal Refl ux Symptoms: A Nationwide Multi-Center Prospective Study. Gut and Liver, 2011, 5, 437-446.	1.4	31
943	Rifaximin Plus Levofloxacin-Based Rescue Regimen for the Eradication of Helicobacter pylori. Gut and Liver, 2012, 6, 452-456.	1.4	16
944	Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection. Gut and Liver, 2015, 9, 478.	1.4	18
945	Korean Red Ginseng: Qualitative and Quantitative Benefits on Helicobacter pylori Infection. Journal of Ginseng Research, 2010, 34, 77-88.	3.0	4
946	Efficacy of Korean Red Ginseng Supplementation on Eradication Rate and Gastric Volatile Sulfur Compound Levels after Helicobacter pylori Eradication Therapy. Journal of Ginseng Research, 2010, 34, 122-131.	3.0	13
947	Rapid detection of clarithromycin-resistant <i>Helicobacter pylori</i> in patients with dyspepsia by fluorescent in situ hybridization (FISH) compared with the E-test. Annals of Saudi Medicine, 2007, 27, 84-88.	0.5	12
948	Standard triple therapy in Helicobacter pylori eradication in Turkey: Systematic evaluation and meta-analysis of 10-year studies. Turkish Journal of Gastroenterology, 2019, 30, 420-435.	0.4	20
949	Antibiotic resistance of Helicobacter pylori from patients in Ile-Ife, South-west, Nigeria. African Health Sciences, 2007, 7, 143-7.	0.3	35
950	Prevalence of Helicobacter pylori in Southern Part of Iran. Jundishapur Journal of Microbiology, 2018, 11, .	0.2	3
951	Improving Helicobacter pylori Eradication Regimens. Annals of Internal Medicine, 2006, 144, 140.	2.0	6
952	&lt;i>Helicobacter pylori</i> Infection among Children with Phenylketonuria. Japanese Journal of Infectious Diseases, 2013, 66, 433-435.	0.5	1
953	GIST of the stomach masquerading as recurrent falls in an older adult: a case report and review. BMC Gastroenterology, 2021, 21, 381.	0.8	0
954	V Spanish Consensus Conference on Helicobacter pylori infection treatment. GastroenterologÃa Y HepatologÃa (English Edition), 2021, , .	0.0	0
956	Probiotics as the live microscopic fighters against Helicobacter pylori gastric infections. BMC Gastroenterology, 2021, 21, 388.	0.8	35
957	Erkrankungen des Magen-Darm-Traktes. , 2003, , 715-861.		0
958	Priorities for further research in Helicobacter pylori management â€” the way forward. , 2003, , 523-526.		0
959	Management of Helicobacter pylori infection â€” a review of the available regional and national guidelines. , 2003, , 447-462.		0
960	Helicobacter pylori should be eradicated in patients receiving long-term acid suppression. , 2003, , 301-310.		0

#	ARTICLE	IF	CITATIONS
962	What constitutes failure of H. pylori eradication therapy?. , 2003, , 391-400.		0
963	Progress in our understanding of H. pylori infection and gastritis. , 2003, , 115-126.		0
964	Helicobacter pylori management: how to improve the therapeutic confusion in practice. , 2003, , 423-431.		0
965	Global consensus update for managing Helicobacter pylori infection: critical issues from the United States. , 2003, , 489-496.		0
966	Eradication therapy should be different for dyspeptic patients compared with ulcer patients. , 2003, , 353-361.		0
967	H. pylori infection: Clinical management from a European perspective. , 2003, , 475-480.		0
968	Erkrankungen des Magens und des Zwölffingerdarms. , 2003, , 673-685.		0
969	What are the global response rates to Helicobacter pylori eradication therapy?. , 2003, , 329-338.		0
970	Helicobacter pylori eradication in non-ulcer dyspepsia: the case for. , 2003, , 265-274.		0
971	How can the current strategies for eradication therapy be improved?. , 2003, , 401-411.		0
972	A proposal for future Helicobacter pylori eradication guidelines. , 2003, , 503-512.		0
973	Pharmacotherapy of Helicobacter pylori-associated gastritis. , 2004, , 1-16.		0
974	Drug-Resistant Helicobacter pylori. , 2004, , 141-157.		0
975	Hereditary Diffuse Gastric Cancer Syndrome. , 2004, , 600-604.		0
976	STOMACH   Disorders. , 2005, , 190-195.		0
978	Influence of various proton pump inhibitors on intestinal metaplasia in noneradicated Helicobacter pylori patients. World Journal of Gastroenterology, 2005, 11, 2334.	1.4	1
979	Gastroduodenale Erkrankungen. , 2005, , 695-732.		0
980	Prevention of Cancers of the Esophagus and Stomach. , 2005, , 25-54.		1

#	ARTICLE	IF	CITATIONS
982	The Serological Gastric Biopsy: A Non-endoscopical/Histopathologic Diagnostic Approach in Management of the Dyspeptic Patients. American Journal of Immunology, 2006, 2, 88-96.	0.1	2
983	Is the string test a useful alternative to gastroscopy with biopsy for H. pylori identification?. Revista Espanola De Enfermedades Digestivas, 2006, 98, 542-9.	0.1	2
984	Gastroduodenale Erkrankungen. , 2007, , 763-804.		0
985	El dolor abdominal en la prÁctica clÁnica. , 2007, , 775-800.		0
987	Functional dairy products for gastrointestinal infections and dysfunction. , 2007, , 63-89.		1
988	Ä–sophagus und Magen. , 2008, , 411-428.		0
989	Helicobacter pylori Infection. , 2008, , 98-113.		0
991	OrientaÃ–o inicial da dispepsia ao nÃvel dos cuidados de saÃde primÃrios. RevisÃo sistemÃtica. Revista Portuguesa De ClÁnica Geral, 2008, 24, 181-205.	0.1	0
992	CumulativeH. pyloriEradication Rates in Clinical Practice by Adopting First- and Second-Line Regimens Proposed by the Maastricht III Consensus and a Third-Line Empirical Regimen. American Journal of Gastroenterology, 2008, , .	0.2	0
993	Gastro-enterologie. , 2009, , 150-176.		0
994	In Vitro Performance and Analysis of Combination Anti-infective Evaluations. , 2009, , 1135-1149.		0
995	Prevention of Upper Gastrointestinal Tract Cancers. , 2010, , 145-174.		1
997	Maag-, darm- en leverziekten. , 2010, , 384-415.		0
998	Such a Lot of Reasons Why H. pylori Should Be Eradicated: To Avoid the Risks Being Passed to Our Children and Grandchildren. Health Evaluation and Promotion, 2010, 37, 664-670.	0.0	0
999	Maag-, darm- en leverziekten. , 2011, , 396-433.		0
1000	Antimicrobial Resistance ofHelicobacter pylorisolated from Korean Children. Korean Journal of Pediatric Gastroenterology and Nutrition, 2011, 14, 45.	0.2	3
1001	NSAIDs and Peptic Ulcer Disease. , 0, , .		2
1002	Sequential and concomitant non-bismuth quadruple therapies are ineffective for &lt;i>H. pylori&lt;/i>; eradication in Palestine. A randomized trial. Open Journal of Gastroenterology, 2012, 02, 177-180.	0.1	1

#	ARTICLE	IF	CITATIONS
1003	Non-Hodgkin's Lymphoma. , 2012, , 1545-1572.		0
1004	Helicobacter pylori Infection and Undiagnosed Dyspepsia in Dyspeptic Populations Under 45 of Age Tested by ELISA, Urease Breath Test and Helicotest. , 0, , .		0
1005	Serological Diagnosis of Certain Human, Animal and Plant Diseases. , 2012, , .		2
1007	Comparison of Azithromycin and Clarithromycin Triple Therapy Regimens for Helicobacter Pylori Eradication in hemodialysis Patients. Nephro-Urology Monthly, 2012, 4, 571-577.	0.0	4
1009	The Patientsâ€™ Adherence and Adverse Drug Reactions (ADRs) which are Caused by Helicobacter Pylori Eradication Regimens. Journal of Clinical and Diagnostic Research JCDR, 2013, 7, 462-6.	0.8	11
1010	Suppression of Helicobacter Pylori in Mice Intestine by Ingestion of Lactic Acid Bacteria in Yoghurt. IOSR Journal of Dental and Medical Sciences, 2014, 13, 09-12.	0.0	0
1012	Efficacy of Bismuth-Containing Quadruple Therapy as First-line Treatment for Helicobacter pylori Infection. Euroasian Journal of Hepato-gastroenterology, 2012, 2, 90-93.	0.1	1
1013	A prediction study between patients with the presence of alarm symptoms and organic pathology in upper gastrointestinal tract endoscopy. Endoskopi Gastrointestinal, 2015, 23, 44-49.	0.0	0
1014	Addition of Rifaximin and N-Acetyl Cysteine to the Standard Helicobacter pylori Treatment Regimens: Is it Possible to Improve Outcomes?. Journal of Gastric Disorders and Therapy, 2016, 2, .	0.1	0
1015	Quadruple Therapy. , 2016, , 437-445.		0
1016	The effectiveness of various schemes of eradication therapy in children with helicobacter-asociated diseases of upper gastrointestinal tract. ScienceRise, 2016, 2, 58.	0.1	0
1017	In Vitro Performance and Analysis of Combination Anti-infective Evaluations. , 2017, , 1329-1345.		1
1018	"HELICARB" - the first Russian breath test kit with 99 % <sup>13</sup>C-urea for Helicobacter pylori: from idea to registration. Klinicheskaia Meditsina, 2017, 95, 78-84.	0.2	2
1019	Role of Camphlobacter pylori and non steroidal anti-inflammatory drugs in the pathogenesis of peptic ulcer and pharmacological approaches for the treatment of peptic ulcer disease. Gastroenterology & Hepatology (Bartlesville, Okla ), 2019, 10, .	0.0	0
1020	Case Histories of Significant Medical Advances: Eradicating Helicobacter Pylori Infections to Treat Ulcers. SSRN Electronic Journal, 0, , .	0.4	0
1021	Erosive And Non-Erosive Forms Of Gastroesophageal Reflux Disease. Shidnoevropejskij Zurnal Vnutrisnoi Ta Simejnoi Medicini, 2019, 2019, 42-49.	0.0	0
1022	Serological Biomarker Panel in Diagnosis of Atrophic Gastritis and <i>Helicobacter pylori</i> Infection in Gastroscopy Referral Patients: Clinical Validation of the New-Generation GastroPanel<sup>Â®</sup>Test. Anticancer Research, 2021, 41, 5527-5537.	0.5	11
1025	Erkrankungen des Magens und des ZwÃ¼lffingerdarms. , 2005, , 710-723.		0

#	ARTICLE	IF	CITATIONS
1027	Klinik und Therapie der Helicobacter-pylori-Infektion. , 2006, , 171-183.		1
1028	Helicobacter pylori Pathogenesis and Vaccines. , 2008, , 195-218.		0
1030	Eradication of Helicobacter pylori: a clinical update. MedGenMed: Medscape General Medicine, 2004, 6, 19.	0.2	21
1032	The antibacterial activity of honey on helicobacter pylori. Sultan Qaboos University Medical Journal, 2006, 6, 71-6.	0.3	11
1034	Prevalence of helicobacter pylori infection in children, a population-based cross-sectional study in west iran. Iranian Journal of Pediatrics, 2013, 23, 13-8.	0.1	36
1035	Knowledge and Practice of General Practitioners and Internists about Helicobacter pylori infection in Guilan, Iran. Middle East Journal of Digestive Diseases, 2011, 3, 119-25.	0.2	3
1036	Replacement of clarithromycin with azithromycin in triple therapy regimens for the eradication of Helicobacter pylori: A randomized clinical trial. Journal of Medicine and Life, 2014, 7, 254-9.	0.4	8
1037	Toxicosis in Helicobacter Pylori infection - a hypothesis. Clujul Medical, 2013, 86, 213-6.	0.1	0
1038	The Helicobacter pylori eradication in the group receiving standard -dose and group continue taking amoxicillin for 4 weeks; a clinical trial study. Gastroenterology and Hepatology From Bed To Bench, 2015, 8, S54-9.	0.6	3
1039	When human cells meet bacteria: precision medicine for cancers using the microbiota. American Journal of Cancer Research, 2018, 8, 1157-1175.	1.4	9
1040	Formulary Substitution of Proton Pump Inhibitors Based on Acquisition Price: Changes in Usage and Costs of Acid-Suppressant Therapies. P and T, 2006, 31, 716-734.	1.0	0
1041	Tailored susceptibility-guided therapy via gastric juice PCR for the first-line H. pylori eradication, a randomized controlled trial. Journal of the Formosan Medical Association, 2022, 121, 1450-1457.	0.8	10
1042	DĂ©pistage de Helicobacter pylori: endoscopie ou sĂ©rologie?. Bio Tribune Magazine, 2007, 25, 37-42.	0.2	0
1043	Current development of <i>Helicobacter pylori</i>; eradication protocols. Russian Journal of Infection and Immunity, 2022, 11, 1037-1049.	0.2	2
1044	Who Could Be Blamed in the Case of Discrepant Histology and Serology Results for Helicobacter pylori Detection?. Diagnostics, 2022, 12, 133.	1.3	7
1045	Rapid Detection of Quinolone Resistance Mutations in gyrA of Helicobacter pylori by Real-Time PCR. Pathogens, 2022, 11, 59.	1.2	6
1046	Worldwide and Regional Efficacy Estimates of First-line Helicobacter pylori Treatments. Journal of Clinical Gastroenterology, 2022, 56, 114-124.	1.1	14
1047	Evaluation of the diagnostic performance and the utility of Helicobacter pylori stool antigen lateral immunochromatography assay. Heliyon, 2022, 8, e09189.	1.4	5

#	ARTICLE	IF	CITATIONS
1048	Bacterial metallo-aminopeptidases as targets in human infectious diseases. <i>Current Drug Targets</i> , 2022, 23, .	1.0	1
1049	In vitro antimicrobial activity of douro wines against clinical <i>Helicobacter Pylori</i> Strains. <i>Nova</i> , 2021, 19, 121-134.	0.2	0
1052	The relationship between <i>helicobacter pylori</i> infection and nodular antral gastritis in pediatric patients. <i>Journal of the National Medical Association</i> , 2022, , .	0.6	0
1053	ENHANCEMENT OF SOLUBILITY OF POORLY SOLUBLE DRUG LANSOPRAZOLE. <i>International Journal of Applied Pharmaceutics</i> , 0, , 101-105.	0.3	0
1054	The Effect of Quadruple Therapy with Polaprezinc or Bismuth on Gut Microbiota after <i>Helicobacter pylori</i> Eradication: A Randomized Controlled Trial. <i>Journal of Clinical Medicine</i> , 2022, 11, 7050.	1.0	1
1055	Ten-day concomitant and sequential therapy for <i>Helicobacter pylori</i> effective in region with high antibiotic resistance rates. <i>Indian Journal of Gastroenterology</i> , 2022, 41, 627-633.	0.7	2
1056	Antibiotic Resistance of <i>Helicobacter pylori</i> in Turkey: A Systematic Review and Meta-Analysis. <i>Microbial Drug Resistance</i> , 2023, 29, 96-103.	0.9	3
1067	Quadruple Therapy. , 2023, , 553-562.		0